Psilocybe cubensis

'''Psilocybe cubensis''' ('''magic mushrooms''', '''shrooms''') is a psilocybin-producing basidiomycete fungus in the family Hymenogastraceae and the most widely cultivated [[substance_class:psychoactive/psychedelic]] mushroom species globally{{cite|doi=10.3390/jof11020099|anchor=163c9f07}}. Its principal active constituent, psilocybin, is a [[substance_class:chemical/tryptamine]] [[glossary:prodrug]] converted in the body to [[substance:psilocin]], a [[glossary:partial-agonist]] at [[glossary:serotonin]] [[glossary:5-ht2a]] [[glossary:receptor|receptors]]. Psilocin produces its psychedelic effects by activating cortical 5-HT₂A receptors, disrupting [[glossary:default-mode-network]] connectivity and increasing neural signal entropy{{cite|doi=10.1016/j.tips.2025.08.012|anchor=262baa3c}}. Ceremonial use of [[substance:psilocybin-mushrooms]] by Mesoamerican peoples dates back at least 3,000 years{{cite|doi=10.1556/2054.2019.024|anchor=22fa244b}}. R. Gordon Wasson's participation in a Mazatec ceremony in 1955 brought the species to Western attention; [[article:hofmann|Albert Hofmann]] isolated psilocybin and psilocin in 1958. After decades under [[glossary:schedule-i]] [[glossary:prohibition]], a landmark 2006 controlled trial reignited clinical investigation{{cite|pubmed=16826400|anchor=40c52d8c}}, leading to [[glossary:fda]] Breakthrough Therapy designations and regulated therapeutic frameworks in Oregon and Australia. [[index:effects|Subjective effects]] span [[effect:geometry|visual geometry]] and [[effect:color-enhancement]], [[effect:thought-connectivity]] and [[glossary:introspection]], [[effect:emotional-lability]], and [[effect:ego-dissolution]] or mystical-type experiences. The experience is characteristically introspective and somatically grounded, lasting 4–8 hours with dried oral preparations{{cite|doi=10.1016/s2215-0366(16)30065-7|anchor=61bb4753}}. Unsought effects include acute [[effect:anxiety]] and panic reactions, [[effect:nausea]], and transient [[effect:confusion]] — strongly modulated by [[glossary:set-and-setting]]{{cite|doi=10.3389/fphar.2018.00897|anchor=cdff3310}}. Psilocybin produces no [[glossary:physical-dependence]] and no [[glossary:withdrawal]]; rapid [[glossary:tolerance]] via 5-HT₂A [[glossary:downregulation]] limits compulsive use{{cite|doi=10.1177/0269881108093587|anchor=87e0cbb4}}. The primary risks are psychological — acute anxiety reactions and, rarely, persisting [[glossary:psychosis]] in predisposed individuals — rather than physiological, as no human fatalities from psilocybin [[glossary:toxicity]] alone are documented{{cite|doi=10.1177/0269881108093587|anchor=4e5ef022}}. Alkaloid content varies 2–4-fold across individual fruiting bodies even within a single batch{{cite|doi=10.3390/ijms232214068|anchor=0fe494a3}}, complicating dose prediction for uncharacterized material.

'''Psilocybe cubensis''' ('''magic mushrooms''', '''shrooms''') is a psilocybin-producing fungus in the family Hymenogastraceae and the most widely cultivated [[substance_class:psychoactive/psychedelic]] mushroom species globally{{cite|doi=10.3390/jof11020099|anchor=4fce7fe7}}. Its principal active constituents — psilocybin (a [[glossary:prodrug]]) and its [[glossary:active-metabolite]] [[substance:psilocin]] — are [[substance_class:chemical/indole]] [[substance_class:chemical/tryptamine|tryptamines]] acting primarily as [[glossary:partial-agonist|partial agonists]] at [[glossary:serotonin]] [[glossary:5-ht2a]] [[glossary:receptor|receptors]]. Dried fruiting bodies consumed orally in several preparation forms produce psychedelic effects lasting 4–8 hours{{cite|doi=10.1016/s2215-0366(16)30065-7|anchor=3b307dea}}. Ceremonial use of psilocybin-containing mushrooms by Mesoamerican indigenous peoples is documented archaeologically for at least 3,000 years{{cite|doi=10.1556/2054.2019.024|anchor=32dbef4f}}. First scientifically described as ''Stropharia cubensis'' by Franklin Sumner Earle in 1906, the species entered Western [[glossary:awareness]] through R. Gordon Wasson's participation in a Mazatec ceremony in 1955. After U.S. [[glossary:schedule-i]] classification in 1970 halted research for decades, a landmark 2006 [[glossary:controlled-study]] re-established clinical investigation{{cite|pubmed=16826400|anchor=170ef3b8}}. Multiple [[glossary:randomized-controlled-trial|randomized controlled trials]] for treatment-resistant [[effect:depression]], cancer-related [[glossary:distress]], and [[glossary:substance-use-disorder|substance use disorders]] have since reported significant [[glossary:efficacy]]. [[glossary:fda]] Breakthrough Therapy designations for psilocybin (2018–2019), Oregon's regulated therapeutic framework (2020), and Australia's TGA rescheduling to Schedule 8 (2023) mark an accelerating regulatory trajectory. Psilocybin is rapidly dephosphorylated to psilocin by alkaline phosphatases{{cite|doi=10.3390/pharmaceutics17040411|anchor=5e8ae7b5}}. Psilocin crosses the [[glossary:blood-brain-barrier]] and acts as a partial agonist at 5-HT₂A, [[glossary:5-ht1a]], and [[glossary:5-ht2c]] receptors, with additional [[glossary:trkb|TrkB receptor]] engagement implicated in sustained neuroplastic effects{{cite|doi=10.1016/j.tips.2025.08.012|anchor=26ae92b6}}. Oral [[glossary:bioavailability]] is approximately 52.7%, with psilocin tmax of 1.8–4 hours and an [[glossary:half-life]] of 1.5–4 hours; [[glossary:metabolism]] proceeds primarily via [[glossary:cyp2d6]] and [[glossary:cyp3a4]]{{cite|pubmed=9204776|anchor=37aacb49}}. Effects span perceptual ([[effect:geometry|visual geometry]], [[effect:color-enhancement]], [[effect:synesthesia]]), cognitive ([[effect:thought-connectivity]], [[effect:introspection-enhancement]], [[effect:temporal-disorientation]]), emotional ([[effect:euphoria]], [[effect:anxiety]], [[effect:emotional-lability]]), and transpersonal ([[effect:ego-dissolution]], mystical-type experiences) domains. Effects and duration vary substantially by preparation method, dose, individual [[glossary:sensitivity]], and the well-documented influence of [[glossary:set-and-setting]]{{cite|doi=10.3389/fphar.2018.00897|anchor=4ee2ba2f}}. Psilocybin has low acute physiological [[glossary:toxicity]]; no human fatalities from psilocybin toxicity alone are documented in the peer-reviewed literature{{cite|doi=10.1177/0269881108093587|anchor=5ed09f9b}}. The substance produces no [[glossary:physical-dependence]] and no clinically recognized [[glossary:withdrawal]]. Rapid [[glossary:tachyphylaxis]] via 5-HT₂A [[glossary:downregulation]] limits compulsive use. Primary risks are psychological: acute anxiety and panic reactions, rare persisting [[glossary:psychosis]] in predisposed individuals, and [[glossary:hppd]] (HPPD). Concurrent [[substance_class:pharmacological/monoamine-oxidase-inhibitor]] use poses hypertensive emergency risk, amplified by [[glossary:endogenous]] β-carboline monoamine oxidase inhibitors present in the mushroom matrix{{cite|doi=10.1002/chem.201904363|anchor=fdda93fb}}. Alkaloid content varies 2–4-fold across individual fruiting bodies even within a single cultivation batch{{cite|doi=10.3390/ijms232214068|anchor=03646a5e}}, complicating dose standardization for uncharacterized material.

'''Psilocybe cubensis''' ('''magic mushrooms''', '''shrooms''') is a psilocybin-producing mushroom in the family Hymenogastraceae — the most widely cultivated [[substance_class:psychoactive/psychedelic]] fungus globally{{cite|doi=10.3390/jof11020099|anchor=0c3c6449}}. Its principal active constituent, psilocybin, is converted in the body to [[substance:psilocin]]. Psilocin activates [[glossary:serotonin]] [[glossary:receptor|receptors]] in the [[glossary:prefrontal-cortex]], disrupting the brain's default network and producing the [[glossary:psychedelic-experience]]{{cite|doi=10.1016/j.tips.2025.08.012|anchor=77789bf0}}. Ceremonial use of [[substance:psilocybin-mushrooms]] by Mesoamerican peoples dates back at least 3,000 years{{cite|doi=10.1556/2054.2019.024|anchor=b7712a14}}. R. Gordon Wasson's 1957 publication in ''Life'' magazine brought the mushroom to Western attention; [[article:hofmann|Albert Hofmann]] isolated psilocybin and psilocin the following year{{cite|doi=10.3390/molecules26102948|anchor=4674ba82}}. After decades under [[glossary:schedule-i]] [[glossary:prohibition]], clinical research resumed in 2006 and has since produced [[glossary:fda]] Breakthrough Therapy designations and regulated therapeutic access in Oregon and Australia{{cite|pubmed=16826400|anchor=e9ce5824}}. [[index:effects|Subjective effects]] include brightened colours, flowing [[effect:geometry|visual geometry]], heightened emotional [[glossary:sensitivity]], [[effect:thought-connectivity]], and — at higher doses — [[effect:ego-dissolution]] and mystical-type experiences. The experience is characteristically introspective and body-centred, shaped powerfully by mindset and environment{{cite|doi=10.3389/fphar.2018.00897|anchor=ed85fbc4}}. Unwanted effects include [[effect:nausea]] at onset, acute [[effect:anxiety]] and panic reactions, and transient [[effect:confusion]]. Psilocybin produces no [[glossary:physical-dependence]] and no [[glossary:withdrawal]], and no human fatalities from psilocybin [[glossary:toxicity]] alone are documented{{cite|doi=10.1177/0269881108093587|anchor=cccb016d}}. The primary dangers are psychological — acute anxiety reactions and, rarely, lasting [[glossary:psychosis]] in people with a personal or family history of psychotic [[glossary:disorder|disorders]]. [[glossary:potency]] varies 2–4-fold between individual fruiting bodies even within a single batch{{cite|doi=10.3390/ijms232214068|anchor=b274127f}}, making dose prediction difficult with uncharacterised material.

===Discovery and early record=== ''Psilocybe cubensis'' was first described scientifically by Franklin Sumner Earle in 1906 from specimens collected in Cuba, under the name ''Stropharia cubensis'' Earle{{cite|name=gbif-psilocybe-cubensis|type=book|author=GBIF|year=2024|title=Psilocybe cubensis taxonomy|anchor=d0c8b79c}}. Rolf Singer transferred the species to the genus ''Psilocybe'' in 1949, establishing the currently accepted binomial ''Psilocybe cubensis'' (Earle) Singer. Gastón Guzmán's monograph ''The Genus Psilocybe'' (1983) remains the definitive taxonomic treatment, describing approximately 144 species at publication{{cite|name=guzman-psilocybe-1983|type=book|author=Guzmán G|year=1983|title=The Genus Psilocybe|anchor=42a0d67b}}. ===Traditional use=== Archaeological evidence of ceremonial psilocybin mushroom use by Mesoamerican indigenous peoples extends at least 3,000–3,500 years, based on mushroom-shaped stone effigies found in Guatemala and southern Mexico dating from approximately 1000 BCE to 900 CE{{cite|doi=10.1556/2054.2019.024|anchor=2cac7709}}. The Mazatec people of Oaxaca, Mexico are the best-documented practitioners, referring to [[substance:psilocybin-mushrooms]] as ''teonanácatl'' (Nahuatl: "flesh of the gods") or ''nti si tho'' (Mazatec). Mushrooms were used in the ''Velada'' ceremony — a nocturnal healing ritual — under the guidance of a ''curandera'' or ''curandero''. An annotated bibliography of 49 scholarly works on indigenous psilocybin mushroom practices spans anthropology, history, archaeology, ethnolinguistics, and ethnomycology{{cite|doi=10.1556/2054.2023.00297|anchor=be608ea6}}. ===Western encounter and research=== R. Gordon Wasson, an amateur mycologist and vice president of J.P. Morgan & Co., participated in a Mazatec Velada ceremony with the ''curandera'' María Sabina in Huautla de Jiménez, Oaxaca, in 1955. His account, published in ''Life'' magazine on 13 May 1957, was the first major Western public exposure to psilocybin mushrooms{{cite|name=wasson-life-1957|type=book|author=Wasson RG|year=1957|title=Seeking the Magic Mushroom|anchor=5e9ea289}}. Roger Heim subsequently collected and identified the mushroom specimens, and [[article:hofmann|Albert Hofmann]] at [[article:sandoz|Sandoz]] Laboratories in Basel isolated and chemically characterized psilocybin and [[substance:psilocin]] in 1958, naming both compounds after the ''Psilocybe'' genus{{cite|doi=10.3390/molecules26102948|anchor=669335dd}}. ===Regulatory history and modern era=== Research on psilocybin for psychiatric applications proceeded through the 1960s, including Timothy Leary's Harvard Psilocybin Project (1960–1963). In 1970, psilocybin was classified as [[glossary:schedule-i]] under the U.S. [[glossary:controlled-substances-act]], and the 1971 UN [[glossary:convention-on-psychotropic-substances]] listed psilocybin and psilocin as Schedule I substances — though psilocybin mushrooms themselves were not explicitly listed in the Convention text{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=408a00af}}. Research effectively ceased for three decades until a 2004 UCLA pilot study in cancer patients with [[effect:anxiety]] reignited clinical interest. The landmark Griffiths et al. (2006) [[glossary:double-blind]] study at Johns Hopkins demonstrated that psilocybin (30 mg/70 kg) reliably occasioned mystical-type experiences in healthy volunteers, with 67% rating the session among their five most personally meaningful life experiences at two-month follow-up{{cite|pubmed=16826400|anchor=c1d4c2ef}}. Subsequent milestones include: [[glossary:fda]] Breakthrough Therapy designations for psilocybin in treatment-resistant [[effect:depression]] (Compass Pathways, 2018) and major depressive [[glossary:disorder]] (Usona Institute, 2019); Oregon Measure 109 establishing regulated psilocybin services (passed 2020, first centers opened 2023); Colorado Proposition 122 decriminalizing personal use (2022); Australia's TGA rescheduling psilocybin to Schedule 8 for authorized psychiatric prescribing effective July 2023{{cite|name=tga-rescheduling-2023|type=book|author=Therapeutic Goods Administration|year=2023|title=Change of classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists|anchor=b742ecb2}}; and the [[glossary:drug-enforcement-administration|DEA]] forwarding a petition to reschedule psilocybin from Schedule I to [[glossary:schedule-ii]] in August 2025.

===Traditional and historical use=== Archaeological evidence places ceremonial psilocybin mushroom use by Mesoamerican indigenous peoples at least 3,000–3,500 years into the past, based on mushroom-shaped stone effigies from Guatemala and southern Mexico dating from approximately 1000 BCE to 900 CE{{cite|doi=10.1556/2054.2019.024|anchor=56c319c5}}. The Mazatec people of Oaxaca, Mexico are the best-documented practitioners, using [[substance:psilocybin-mushrooms]] — called ''teonanácatl'' (Nahuatl: "flesh of the gods") — in the ''Velada'', a nocturnal healing ceremony guided by a ''curandera'' or ''curandero''. An annotated bibliography spanning 49 scholarly works documents indigenous psilocybin practices across anthropology, archaeology, ethnolinguistics, and ethnomycology{{cite|doi=10.1556/2054.2023.00297|anchor=866e4183}}. ===Western discovery and research=== R. Gordon Wasson, an amateur mycologist and J.P. Morgan vice president, participated in a Mazatec Velada ceremony with the ''curandera'' María Sabina in 1955 and published his account in ''Life'' magazine in May 1957 — the first major Western public exposure to psilocybin mushrooms{{cite|name=wasson-life-1957|type=book|author=Wasson RG|year=1957|title=Seeking the Magic Mushroom|anchor=5631fab1}}. Roger Heim collected and identified the specimens, and [[article:hofmann|Albert Hofmann]] at [[article:sandoz|Sandoz]] Laboratories isolated and characterized psilocybin and [[substance:psilocin]] in 1958, naming both compounds after the ''Psilocybe'' genus{{cite|doi=10.3390/molecules26102948|anchor=2927dec2}}. ===Modern era=== Psilocybin was classified as [[glossary:schedule-i]] under the U.S. [[glossary:controlled-substances-act]] in 1970, and the 1971 UN [[glossary:convention-on-psychotropic-substances]] listed psilocybin and psilocin as Schedule I — though psilocybin mushrooms themselves were not explicitly named in the Convention text{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=d9e6347d}}. Research effectively ceased for three decades until a 2006 [[glossary:double-blind]] study at Johns Hopkins demonstrated that psilocybin reliably occasioned mystical-type experiences, with 67% of volunteers rating the session among their five most personally meaningful life experiences{{cite|pubmed=16826400|anchor=f34f9df6}}. Subsequent milestones include [[glossary:fda]] Breakthrough Therapy designations for treatment-resistant [[effect:depression]] (2018) and major depressive [[glossary:disorder]] (2019), Oregon's regulated psilocybin services framework (first centres opened 2023), Colorado's decriminalization of personal use (2022), and Australia's TGA rescheduling to Schedule 8 for authorised psychiatric prescribing{{cite|name=tga-rescheduling-2023|type=book|author=Therapeutic Goods Administration|year=2023|title=Change of classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists|anchor=c40b0c8e}}. {{DiscoverMore|Indigenous and traditional use}} The Mazatec ''Velada'' is a nocturnal healing ceremony in which a ''curandera'' ingests psilocybin mushrooms and [[glossary:channel|channels]] the experience to diagnose or treat illness. The mushrooms were called ''nti si tho'' in Mazatec. María Sabina, the ''curandera'' who shared the ceremony with Wasson, later expressed regret at the cultural [[glossary:disruption]] that followed Western publication. Scholarly documentation of indigenous psilocybin practices spans multiple disciplines{{cite|doi=10.1556/2054.2023.00297|anchor=baa3eaa9}}. {{/DiscoverMore}}

===Traditional and historical use=== Archaeological evidence places ceremonial psilocybin mushroom use in Mesoamerica at least 3,000–3,500 years in the past, based on mushroom-shaped stone effigies from Guatemala and southern Mexico dating from around 1000 BCE to 900 CE{{cite|doi=10.1556/2054.2019.024|anchor=6db3a6c9}}. The Mazatec people of Oaxaca used [[substance:psilocybin-mushrooms]] — called ''teonanácatl'' ("flesh of the gods" in Nahuatl) — in the ''Velada'', a nocturnal healing ceremony guided by a ''curandera''. Scholarly documentation of indigenous practices spans anthropology, archaeology, ethnolinguistics, and ethnomycology{{cite|doi=10.1556/2054.2023.00297|anchor=ed839e19}}. ===Western discovery and research=== R. Gordon Wasson participated in a Mazatec Velada ceremony with the ''curandera'' María Sabina in 1955 and published his account in ''Life'' magazine in 1957 — the first major Western public exposure to psilocybin mushrooms{{cite|name=wasson-life-1957|type=book|author=Wasson RG|year=1957|title=Seeking the Magic Mushroom|anchor=301fbf33}}. Roger Heim collected and identified the specimens; [[article:hofmann|Albert Hofmann]] at [[article:sandoz|Sandoz]] Laboratories isolated psilocybin and [[substance:psilocin]] in 1958{{cite|doi=10.3390/molecules26102948|anchor=b808eaa0}}. ===Modern era=== Psilocybin was classified as [[glossary:schedule-i]] in the US in 1970, and the 1971 UN Convention listed psilocybin and psilocin — though the mushrooms themselves were not explicitly named{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=9934de6d}}. Research effectively halted for three decades until a 2006 Johns Hopkins trial showed psilocybin reliably occasioned meaningful mystical-type experiences, with 67% of volunteers rating the session among their five most personally meaningful life experiences{{cite|pubmed=16826400|anchor=21249299}}. Subsequent milestones include [[glossary:fda]] Breakthrough Therapy designations for [[effect:depression]], Oregon's regulated psilocybin services framework (first centres opened 2023), and Australia's rescheduling to permit psychiatric prescribing{{cite|name=tga-rescheduling-2023|type=book|author=Therapeutic Goods Administration|year=2023|title=Change of classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists|anchor=be4ea9ba}}. {{DiscoverMore|Indigenous and traditional use}} The Mazatec ''Velada'' is a nocturnal healing ceremony in which a ''curandera'' ingests psilocybin mushrooms and [[glossary:channel|channels]] the experience to diagnose or treat illness. The mushrooms were called ''nti si tho'' in Mazatec. María Sabina, the ''curandera'' who shared the ceremony with Wasson, later expressed regret at the cultural [[glossary:disruption]] that followed Western publication. Scholarly documentation of indigenous psilocybin practices spans multiple disciplines{{cite|doi=10.1556/2054.2023.00297|anchor=f83e2d5c}}. {{/DiscoverMore}}

''Psilocybe cubensis'' is a basidiomycete fungus, not a botanical plant; the Psychedex database classifies it under the plant article shape as a convention for non-[[glossary:synthetic]] substance articles. The species was historically placed in Strophariaceae but has been reassigned to Hymenogastraceae on the basis of molecular phylogenetic evidence{{cite|name=gbif-psilocybe-cubensis|type=book|author=GBIF|year=2024|title=Psilocybe cubensis taxonomy|anchor=aebd7d80}}. Additional synonyms include ''Stropharia cyanescens'' Murrill, ''Hypholoma caerulescens'' Pat., and ''Naematoloma caerulescens''. Phylogenomic analysis of 2,983 single-copy gene families from 71 metagenomes — including 23 type specimens — established that the stem [[glossary:lineage]] of ''Psilocybe'' arose approximately 67 million years ago and diversified around 56 mya. The psilocybin biosynthetic gene cluster first arose within ''Psilocybe'', with 4–5 probable horizontal gene transfers to other mushroom genera between 40 and 9 mya{{cite|doi=10.1073/pnas.2311245121|anchor=54e76628}}. ''P. cubensis'' is widely distributed in tropical and subtropical regions — primarily Mexico, Central America, northern South America, the southern United States (Texas, Florida, Louisiana), Southeast Asia (Thailand, Vietnam, Cambodia), and Australia. It is a coprophilous species, growing naturally on the dung of large herbivores — particularly cattle and buffalo — in warm, humid environments{{cite|doi=10.3390/jof11020099|anchor=dab5fb09}}. ===Morphology=== The cap (pileus) is 1.5–8 cm broad, conical to broadly umbonate when young, becoming broadly convex to plane with age. Cap color is pale yellowish-brown to golden-brown, often fading to whitish at the margin; the surface is viscid when moist. The stipe is 4–15 cm long and 0.4–1.4 cm thick, whitish, sometimes bruising blue. Gills are adnate to adnexed, grayish when young, becoming deep purplish-brown to nearly black as spores mature. The '''bluing reaction''' — tissue turning blue or blue-green on bruising — results from oxidative dimerization of [[substance:psilocin]] and serves as a useful field identification marker{{cite|doi=10.3389/ffgc.2022.813998|anchor=19c260fb}}. ===Misidentification risks=== Wild-harvested [[substance:psilocybin-mushrooms]] carry a significant risk of [[effect:confusion]] with toxic species: * ''Galerina marginata'' and related species contain amatoxins (α-amanitin) and can be fatal. Distinguished from ''Psilocybe'' by a rusty-brown spore print (versus purplish-black), absence of bluing reaction, and a ring with fine dark fibrils{{cite|doi=10.3389/ffgc.2022.813998|anchor=3a354f85}}. * ''Pholiota'' species — bitter taste, no bluing reaction, rusty-brown spores. * Toxic ''Cortinarius'' species — occur in overlapping geographic ranges in some regions. ===Cultivar variation=== Commercially named cultivar strains (Golden Teacher, B+, Penis Envy, Amazonian, Ecuador) are not formally recognized taxonomic entities. Both genetics and environmental cultivation conditions — [[glossary:substrate]] composition, temperature, humidity, light cycle — significantly affect alkaloid biosynthesis{{cite|doi=10.3390/jof11020099|anchor=0cfc1d79}}. The Penis Envy cultivar is widely reported as higher-[[glossary:potency]] in community settings; however, peer-reviewed comparative HPLC quantification across named cultivars under matched conditions remains limited.{{flag|citation-needed}}

''Psilocybe cubensis'' (Earle) Singer belongs to the family Hymenogastraceae. First described as ''Stropharia cubensis'' by Franklin Sumner Earle in 1906 from Cuban specimens{{cite|name=gbif-psilocybe-cubensis|type=book|author=GBIF|year=2024|title=Psilocybe cubensis taxonomy|anchor=ad899e89}}, the species was transferred to ''Psilocybe'' by Rolf Singer in 1949. Gastón Guzmán's 1983 monograph ''The Genus Psilocybe'' remains the authoritative taxonomic treatment, describing approximately 144 species at publication{{cite|name=guzman-psilocybe-1983|type=book|author=Guzmán G|year=1983|title=The Genus Psilocybe|anchor=e8562579}}. ''P. cubensis'' is a coprophilic, subtropical-to-tropical species found naturally across Central America, South America, Southeast Asia, and northern Australia, typically fruiting from cattle or horse dung in warm, humid pastures. It is the most widely cultivated psilocybin mushroom, owing to vigorous growth on simple [[glossary:substrate|substrates]] (brown rice flour, vermiculite, pasteurised grain) and [[glossary:tolerance]] of variable growing conditions. The mature fruiting body has a convex to broadly umbonate cap, 2–8 cm in diameter, ranging from pale golden to caramel brown and often developing a darker centre. The stipe is 4–15 cm long, whitish, and bruises blue-green when damaged — a hallmark bluing reaction indicating psilocybin-containing tissue. The spore print is purplish-black to dark brown. The critical identification concern for wild foragers is distinguishing ''Psilocybe'' from the [[glossary:hepatotoxicity|hepatotoxic]] ''Galerina marginata'', which contains lethal amatoxins{{cite|doi=10.3389/ffgc.2022.813998|anchor=6d7c2455}}. The most reliable field-level discriminators are spore print colour (purplish-black for ''Psilocybe'' versus rusty-brown for ''Galerina'') and the presence of the bluing reaction on damaged tissue. Fruiting bodies are typically harvested just before or shortly after the veil breaks and dried for storage. Drying preserves alkaloid content for months to years. Fresh mushrooms contain approximately 90% water by weight, so 1 g dried material corresponds to roughly 10 g fresh.

''Psilocybe cubensis'' (Earle) Singer belongs to the family Hymenogastraceae. First described as ''Stropharia cubensis'' by Franklin Sumner Earle in 1906 from Cuban specimens{{cite|name=gbif-psilocybe-cubensis|type=book|author=GBIF|year=2024|title=Psilocybe cubensis taxonomy|anchor=772d9968}}, it was transferred to ''Psilocybe'' by Rolf Singer in 1949. Gastón Guzmán's 1983 monograph on the genus remains the authoritative taxonomic treatment{{cite|name=guzman-psilocybe-1983|type=book|author=Guzmán G|year=1983|title=The Genus Psilocybe|anchor=8a340faf}}. ''P. cubensis'' is a subtropical-to-tropical species found naturally across Central America, South America, Southeast Asia, and northern Australia, typically fruiting from cattle or horse dung in warm, humid pastures. It is the most widely cultivated psilocybin mushroom, growing vigorously on simple [[glossary:substrate|substrates]] and tolerating variable conditions. The mature cap is convex to broadly umbonate, 2–8 cm across, ranging from pale golden to caramel brown with a darker centre. The stipe is whitish and bruises blue-green when damaged — the hallmark bluing reaction of psilocybin-containing tissue. The critical identification risk for wild foragers is [[effect:confusion]] with ''Galerina marginata'', which contains lethal amatoxins{{cite|doi=10.3389/ffgc.2022.813998|anchor=db6619b7}}. The most reliable discriminators are spore print colour (purplish-black for ''Psilocybe'', rusty-brown for ''Galerina'') and the bluing reaction. Fruiting bodies are typically dried for storage; 1 g dried corresponds to roughly 10 g fresh.

The dominant psychoactive constituent of ''P. cubensis'' is psilocybin (4-phosphoryloxy-''N'',''N''-dimethyltryptamine), a [[substance_class:chemical/tryptamine]] [[glossary:prodrug]] rapidly dephosphorylated in the body to [[substance:psilocin]] (4-hydroxy-''N'',''N''-dimethyltryptamine) by alkaline phosphatases{{cite|doi=10.3390/pharmaceutics17040411|anchor=926f557a}}. Psilocin is the pharmacologically active molecule, acting primarily as a [[glossary:partial-agonist]] at [[glossary:5-ht2a]] [[glossary:serotonin]] [[glossary:receptor|receptors]]{{cite|doi=10.1016/j.tips.2025.08.012|anchor=941187a7}}. Typical dried ''P. cubensis'' fruiting bodies contain 0.5–1.0% psilocybin and 0.1–0.3% psilocin by dry weight, though concentrations vary widely across specimens. The mushroom matrix delivers psilocybin alongside [[glossary:endogenous]] β-carboline alkaloids that function as [[glossary:mao-a]] (MAO-A) [[glossary:inhibitor|inhibitors]]{{cite|doi=10.1002/chem.201904363|anchor=7cedb8bb}}. Because MAO-A participates in psilocin [[glossary:degradation]], these β-carbolines may extend psilocin's effective duration in whole-mushroom preparations relative to [[glossary:synthetic]] psilocybin. This "entourage" interaction is supported by preclinical evidence{{cite|doi=10.1038/s41380-024-02477-w|anchor=f6cbd264}} but has not been quantified in human pharmacokinetic studies. Minor alkaloids identified in ''P. cubensis'' include baeocystin (norpsilocybin), norbaeocystin, and aeruginascin — structurally related tryptamines present at lower concentrations. Their individual contributions to the [[glossary:subjective-experience]] remain poorly characterised, with existing data limited to [[glossary:in-vitro|in vitro]] studies and anecdotal reports. Alkaloid content varies 2–4-fold across individual fruiting bodies even within a single cultivation batch{{cite|doi=10.3390/ijms232214068|anchor=5d24d215}}. Factors influencing [[glossary:potency]] include [[glossary:substrate]] composition, growing conditions, harvest timing, and the specific cultivar or genetic [[glossary:lineage]]. This variability is the primary obstacle to dose standardisation when using uncharacterised mushroom material. Psilocybin's oral [[glossary:bioavailability]] is approximately 52.7%, with psilocin reaching [[glossary:cmax|peak plasma concentration]] (tmax) at 1.8–4 hours and an [[glossary:half-life]] of 1.5–4 hours{{cite|pubmed=9204776|anchor=424ffd8e}}. [[glossary:metabolism]] proceeds primarily via [[glossary:cyp2d6]] and [[glossary:cyp3a4]], with secondary MAO-A contribution{{cite|doi=10.3390/pharmaceutics17040411|anchor=797dd9ee}}.

The dominant psychoactive compound in ''P. cubensis'' is psilocybin — a [[substance_class:chemical/tryptamine]] [[glossary:prodrug]] rapidly converted in the body to [[substance:psilocin]] by alkaline phosphatases{{cite|doi=10.3390/pharmaceutics17040411|anchor=9f2f97cb}}. Psilocin is the active molecule, acting primarily on [[glossary:serotonin]] [[glossary:receptor|receptors]] in the [[glossary:prefrontal-cortex]]{{cite|doi=10.1016/j.tips.2025.08.012|anchor=ae84922d}}. Dried fruiting bodies typically contain 0.5–1.0% psilocybin and 0.1–0.3% psilocin by dry weight, though concentrations vary widely across specimens. The mushroom also contains β-carboline alkaloids that inhibit [[glossary:mao-a]] (MAO-A) — an [[glossary:enzyme]] involved in breaking down psilocin{{cite|doi=10.1002/chem.201904363|anchor=87a2fc91}}. These β-carbolines may extend psilocin's effects in whole-mushroom preparations compared to [[glossary:synthetic]] psilocybin, though this has not been confirmed in human studies{{cite|doi=10.1038/s41380-024-02477-w|anchor=ebe94746}}. Minor alkaloids — baeocystin, norbaeocystin, and aeruginascin — are present at lower concentrations; their individual contributions to the experience are poorly understood. Psilocybin's oral [[glossary:bioavailability]] is approximately 52.7%, peaking in the bloodstream 1.8–4 hours after [[glossary:ingestion]]{{cite|pubmed=9204776|anchor=08e19a63}}. Alkaloid content varies 2–4-fold across individual fruiting bodies even within a single cultivation batch{{cite|doi=10.3390/ijms232214068|anchor=8f53c7bd}}. Growing conditions, [[glossary:substrate]] composition, harvest timing, and cultivar all influence [[glossary:potency]]. This variability is the primary obstacle to accurate dose prediction with uncharacterised mushroom material.

The dominant active constituents of ''Psilocybe cubensis'' are [[substance_class:chemical/indole]] [[substance_class:chemical/tryptamine]] alkaloids derived from L-tryptophan biosynthesis. ===Primary alkaloids=== '''Psilocybin''' (4-phosphoryloxy-N,N-dimethyltryptamine; C₁₂H₁₇N₂O₄P, MW 284.25) is the principal alkaloid by mass and functions as a [[glossary:prodrug]] — enzymatically dephosphorylated to [[substance:psilocin]] by alkaline phosphatases in the intestinal mucosa and blood{{cite|doi=10.3390/pharmaceutics17040411|anchor=51be7791}}. '''Psilocin''' (4-hydroxy-N,N-dimethyltryptamine; C₁₂H₁₆N₂O, MW 204.27) is the pharmacologically [[glossary:active-metabolite]]. It crosses the [[glossary:blood-brain-barrier]] and produces [[substance_class:psychoactive/psychedelic]] effects primarily through [[glossary:5-ht2a]] [[glossary:receptor]] partial agonism{{cite|doi=10.1016/j.tips.2025.08.012|anchor=835df108}}. ===Quantified concentrations=== The largest published systematic alkaloid quantification study analyzed 226 fruiting bodies from 82 collections across 7 genera using ultra-high-performance liquid chromatography coupled with tandem [[glossary:mass-spectrometry]] (UHPLC-MS/MS){{cite|doi=10.3390/ijms232214068|anchor=3b15702f}}. ''Psilocybe'' species exhibited the highest psilocybin and psilocin concentrations among all genera tested. For ''P. cubensis'' specifically, typical dried-weight concentration ranges are approximately '''0.37–1.30% psilocybin''' and '''0.14–0.42% psilocin''' (combined tryptamine content generally 0.5–1.6% by dry weight), though outlier specimens exist. Tryptamine alkaloid concentrations are extremely variable both between species and between individual collections of the same species, representing a substantive dosing risk for consumers using uncharacterized material. ===Minor alkaloids=== '''baeocystin''' (4-phosphoryloxy-N-methyltryptamine; C₁₁H₁₅N₂O₄P, MW 270.22) is the N-demethylated [[glossary:homolog]] of psilocybin, present at lower concentrations. '''norbaeocystin''' (4-phosphoryloxytryptamine; C₁₀H₁₃N₂O₄P, MW 256.19) is a trace alkaloid. '''Aeruginascin''' (4-phosphoryloxy-N,N,N-trimethyltryptammonium) is a quaternary ammonium compound first reported in ''Inocybe aeruginascens'' and subsequently detected in some ''Psilocybe'' species; it has been proposed to modulate [[glossary:subjective-experience]] quality through serotonin₃ receptor agonism{{cite|doi=10.3390/ijms232214068|anchor=1833ce0c}}. ===β-Carboline MAO inhibitors=== ''Psilocybe'' mushrooms simultaneously produce a cocktail of β-carboline [[substance_class:pharmacological/monoamine-oxidase-inhibitor|monoamine oxidase inhibitors]] — including harmane and norharman — as biosynthetic products of L-tryptophan [[glossary:metabolism]]{{cite|doi=10.1002/chem.201904363|anchor=14066ed3}}. MALDI-MS imaging demonstrated that β-carbolines accumulate toward hyphal apices. As potent [[glossary:mao-a]] [[glossary:inhibitor|inhibitors]], these compounds are neuroactive in their own right and slow the oxidative [[glossary:degradation]] of psilocin, potentially extending its effective [[glossary:plasma]] [[glossary:half-life]]. This creates a pharmacological milieu in whole-mushroom preparations that is distinct from [[glossary:synthetic]] psilocybin administered alone. A preclinical comparison of psychedelic mushroom extract (PME) versus chemically synthesized psilocybin in mice found that PME produced similar acute [[glossary:head-twitch-response|head-twitch responses]] but significantly more potent and prolonged [[glossary:neuroplasticity]] markers (GAP43, synaptophysin) in frontal [[glossary:cortex]], [[glossary:hippocampus]], and [[glossary:amygdala]] at 11 days post-treatment{{cite|doi=10.1038/s41380-024-02477-w|anchor=bdd8ceb4}}. Frontal cortex metabolomics showed differential purine profiles, suggesting a gradient of metabolic effect from synthetic psilocybin to whole-mushroom extract. No [[glossary:controlled-study|controlled human study]] has compared the [[glossary:pharmacokinetics]] of whole-mushroom preparations versus synthetic psilocybin.

===Where it acts=== [[substance:psilocin]] crosses the [[glossary:blood-brain-barrier]] and activates [[glossary:serotonin]] [[glossary:receptor|receptors]] concentrated in pyramidal [[glossary:neuron|neurons]] of the [[glossary:prefrontal-cortex]] — the primary mechanism underlying [[substance_class:psychoactive/psychedelic]] effects{{cite|doi=10.1016/j.tips.2025.08.012|anchor=80cda3cf}}. It also engages serotonin receptors linked to calming inhibitory signals{{cite|doi=10.1016/j.neuropharm.2026.110854|anchor=2fda78bc}}, and activates a receptor that promotes [[glossary:neuroplasticity]] — changes in brain connectivity that may persist well beyond the acute experience{{cite|doi=10.1016/j.tips.2025.08.012|anchor=294bb5d3}}. ===What it changes=== The REBUS model proposes that psilocin loosens the brain's top-down predictions, letting raw sensory input drive experience more strongly and increasing the variability of brain signals{{cite|doi=10.1124/pr.118.017160|anchor=bb33f409}}. A single 25 mg dose disrupted brain functional connectivity more than threefold compared to [[substance:methylphenidate]] in precision brain imaging, with the strongest effects in the '''default mode network''' — the system linked to [[glossary:self-referential-thought]]. A decrease in one key connectivity measure persisted for three weeks after the session{{cite|doi=10.1038/s41586-024-07624-5|anchor=38b7a8f2}}. {{DiscoverMore|Open Questions}} * Whole-mushroom [[glossary:pharmacokinetics]] versus [[glossary:synthetic]] psilocybin in humans remain uncharacterised. * The contribution of [[glossary:cyp2d6]] [[glossary:genetic-polymorphism|genetic polymorphisms]] to interindividual variability in psilocybin response has not been established in a [[glossary:genotype]]-stratified study. * Whether [[glossary:endogenous]] β-carbolines in mushroom preparations alter clinical outcomes relative to synthetic psilocybin is unknown. {{/DiscoverMore}}

===Where it acts=== [[substance:psilocin]] crosses the [[glossary:blood-brain-barrier]] and binds [[glossary:5-ht2a]] [[glossary:receptor|receptors]] concentrated in pyramidal [[glossary:neuron|neurons]] of the [[glossary:prefrontal-cortex]] — the primary mechanism underlying [[substance_class:psychoactive/psychedelic]] effects{{cite|doi=10.1016/j.tips.2025.08.012|anchor=8d4294b5}}. Additional engagement of [[glossary:5-ht1a]] receptors contributes to synaptic [[effect:depression]] via enhanced GABAergic signalling{{cite|doi=10.1016/j.neuropharm.2026.110854|anchor=7c7251b9}}, while direct [[glossary:activation]] of [[glossary:trkb]] ([[glossary:bdnf]]) receptors may explain neuroplastic effects persisting well beyond acute drug activity{{cite|doi=10.1016/j.tips.2025.08.012|anchor=fb11d8f9}}. ===What it changes=== The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that psilocin loosens top-down cortical predictions, allowing greater bottom-up sensory influence and increasing entropy in brain signals{{cite|doi=10.1124/pr.118.017160|anchor=b1f131ec}}. Precision fMRI tracking of individual brains found that a single 25 mg psilocybin dose disrupted functional connectivity more than threefold compared to [[substance:methylphenidate]], with the strongest effects in the '''default mode network'''. A persistent decrease in [[glossary:hippocampus|hippocampal]]-[[glossary:default-mode-network]] connectivity lasted three weeks post-session — hypothesised as a neuroanatomical correlate of psilocybin's pro-[[glossary:neuroplasticity|plasticity]] and [[glossary:therapeutic-effect|therapeutic effects]]{{cite|doi=10.1038/s41586-024-07624-5|anchor=02867e19}}. {{DiscoverMore|Open Questions}} * Whole-mushroom [[glossary:pharmacokinetics]] versus [[glossary:synthetic]] psilocybin in humans remain uncharacterised. * The contribution of [[glossary:cyp2d6]] [[glossary:genetic-polymorphism|genetic polymorphisms]] to interindividual variability in psilocybin response has not been established in a [[glossary:genotype]]-stratified study. * Whether [[glossary:endogenous]] β-carbolines in mushroom preparations alter clinical outcomes relative to synthetic psilocybin is unknown. {{/DiscoverMore}}

The ''P. cubensis'' experience is characteristically introspective and somatically grounded — a sense of bodily weight, emotional proximity, and perceptual richness that users frequently describe as "earthy" relative to the more visually architectural character of [[substance:lsd]]. Effects are powerfully shaped by [[glossary:set-and-setting]]; the same dose in a supportive environment versus an unfamiliar social context can produce qualitatively different experiences{{cite|doi=10.3389/fphar.2018.00897|anchor=460e981c}}. Across the [[glossary:dose-range]], low doses produce mood lift and subtle perceptual shifts, moderate doses introduce flowing [[effect:geometry|visual geometry]] and [[effect:thought-connectivity]], and high doses can produce full [[effect:ego-dissolution]] and mystical-type experiences. Compared to LSD, ''P. cubensis'' produces a shorter arc — 4–8 hours versus 8–12 — with a more emotional and body-centred character. Compared to [[glossary:synthetic]] psilocybin administered in clinical settings, whole-mushroom preparations introduce the variable of multi-alkaloid composition and uncontrolled [[glossary:potency]], which may contribute to the wider range of subjective intensities reported at ostensibly equivalent doses{{cite|doi=10.1038/s41380-024-02477-w|anchor=80ec835e}}.

The ''P. cubensis'' experience is characteristically introspective and body-centred — a sense of emotional proximity, bodily weight, and perceptual richness that users frequently describe as "earthy." Effects are powerfully shaped by mindset and environment{{cite|doi=10.3389/fphar.2018.00897|anchor=09ce8291}}. Low doses produce mood lift and subtle perceptual shifts; moderate doses introduce flowing [[effect:geometry|visual geometry]] and [[effect:thought-connectivity]]; high doses can produce full [[effect:ego-dissolution]] and mystical-type experiences. Compared to [[substance:lsd]], ''P. cubensis'' produces a shorter arc with a more emotional, body-centred character and less visual architecture. Compared to [[glossary:synthetic]] psilocybin administered in clinical settings, whole-mushroom preparations introduce multi-alkaloid composition and uncontrolled [[glossary:potency]]{{cite|doi=10.1038/s41380-024-02477-w|anchor=c7bd020c}}, which may explain the wider range of intensities reported at ostensibly equivalent doses.

The following preparation methods are the primary modes of ''Psilocybe cubensis'' consumption documented in harm-reduction literature and clinical practice. Dose values for dried mushroom preparations are derived from community harm-reduction consensus and clinical dose equivalence estimates; they have not been established by a single controlled [[glossary:clinical-study]] specific to dried ''P. cubensis'' mushrooms. Alkaloid content varies approximately 0.5–1.6% total [[substance_class:chemical/tryptamine|tryptamines]] by dry weight{{cite|doi=10.3390/ijms232214068|anchor=5e89203e}}, meaning that 1 gram of dried mushroom corresponds to approximately 5–10 mg psilocybin equivalent — a range wide enough that dose precision cannot be assumed for uncharacterized material. See the Dose by preparation card for structured dose data. ===Dried whole mushroom (oral)=== The most common preparation. Dried fruiting bodies are consumed directly or mixed with food. '''Dose ranges (community-derived estimates):''' * '''Threshold:''' 0.25–0.5 g dried mushroom (~1–5 mg psilocybin equivalent) * '''Light:''' 0.5–1 g (~2.5–10 mg psilocybin equivalent) * '''Common:''' 1–3.5 g (~5–35 mg psilocybin equivalent) * '''Strong:''' 3.5–5 g (~17–50 mg psilocybin equivalent) * '''Heavy:''' >5 g (>25 mg psilocybin equivalent) '''Onset:''' 20–60 minutes. '''Peak:''' 2–3 hours. '''Total duration:''' 4–8 hours{{cite|doi=10.1016/s2215-0366(16)30065-7|anchor=d97ea6af}}. {{flag|safety-citation-needed}} Dose values for dried ''P. cubensis'' are community-derived estimates, not clinically verified values. Clinical reference points using [[glossary:synthetic]] psilocybin: 10 mg produces detectable effects at 30–60 minutes{{cite|doi=10.1016/s2215-0366(16)30065-7|anchor=1eed0730}}; 25 mg is the primary therapeutic dose in Phase 2 trials{{cite|doi=10.1056/nejmoa2206443|anchor=49ffdcca}}; 30 mg/70 kg reliably occasions mystical-type experiences in healthy volunteers{{cite|pubmed=16826400|anchor=8ed2215b}}. ===Mushroom tea (oral infusion)=== Dried or fresh mushrooms steeped in hot water for 10–20 minutes, often with added ginger or lemon to reduce [[effect:nausea]]. Some users report slightly faster onset (~10–15 minutes earlier) and modestly shorter overall duration relative to ingesting dried material directly. Baeocystin and norbaeocystin are water-soluble and are preserved in aqueous extraction. '''Dose ranges:''' Equivalent dried-mushroom weight as above; tea preparation does not substantially alter total alkaloid availability. '''Onset:''' 15–45 minutes. '''Peak:''' 1.5–2.5 hours. '''Total duration:''' 3–6 hours (user reports). {{flag|safety-citation-needed}} No published controlled pharmacokinetic study compares tea versus [[glossary:ingestion|ingested]] dried mushroom in humans. ===Lemon tek (acidified pre-digestion)=== Crushed dried mushrooms soaked in citrus juice (typically lemon or lime) for 15–30 minutes before consumption. Users consistently report faster onset and a shorter, more intense experience. The proposed mechanism — citric acid partially hydrolyzes psilocybin to [[substance:psilocin]] before ingestion, accelerating [[glossary:absorption]] — is chemically plausible but has not been confirmed in a controlled human pharmacokinetic study. '''Dose ranges:''' Users commonly employ 10–30% lower dried-mushroom weight relative to oral ingestion, reflecting the reported intensification. '''Onset:''' 10–30 minutes (user reports). '''Peak:''' 1–2 hours. '''Total duration:''' 3–5 hours (user reports). {{flag|safety-citation-needed}} No peer-reviewed pharmacokinetic data confirms the lemon tek mechanism in humans. ===Capsules and concentrated preparations=== Dried mushroom powder in capsules or standardized extracts are increasingly available in harm-reduction and semi-legal markets. [[glossary:potency]] is highly variable and depends on source material, grinding consistency, and any extraction or concentration steps applied. No systematic published data characterize the [[glossary:pharmacokinetics]] of specific extraction or concentration methods for ''P. cubensis''.

====Toxicity==== Psilocybin has '''low acute physiological toxicity''' — no human fatalities from psilocybin [[glossary:toxicity]] alone are documented{{cite|doi=10.1177/0269881108093587|anchor=76a36d39}}, and the [[glossary:therapeutic-index]] is extremely high relative to typical human doses{{cite|doi=10.3390/molecules26102948|anchor=2ed8222f}}. In clinical trials, the most common [[glossary:adverse-events]] were [[effect:headache]], [[effect:nausea]], and [[effect:dizziness]]{{cite|doi=10.1056/nejmoa2206443|anchor=ceb18a84}}{{cite|doi=10.1001/jama.2023.14530|anchor=917c629d}}. Cardiovascular effects are generally mild and transient; insufficient data exist on safety in patients with established cardiovascular disease{{cite|doi=10.1007/s43440-023-00539-4|anchor=153bcf52}}. Wild foraging carries risk of '''fatal misidentification''' with ''Galerina marginata'', which contains lethal amatoxins{{cite|doi=10.3389/ffgc.2022.813998|anchor=8fd587c7}}. Products sold as psilocybin may be adulterated — NBOMe-series compounds have been detected in pressed tablets and powders. Ehrlich [[glossary:reagent-kit|reagent testing]] confirms [[substance_class:chemical/indole]] presence but cannot identify all [[glossary:synthetic]] imposters; definitive identification requires GC-MS or LC-MS/MS{{cite|doi=10.1016/bs.acc.2016.07.004|anchor=e7c2281d}}. Cultivated mushrooms are susceptible to mould [[glossary:contamination]].{{flag|safety-citation-needed}} ====Psychological Risks==== The most common adverse psychological event is an '''acute anxiety reaction''' — intense fear, [[effect:paranoia]], panic, and [[effect:confusion]]{{cite|doi=10.1177/0269881108093587|anchor=94691351}}. Risk is dose-dependent and context-dependent, reduced by supportive [[glossary:set-and-setting]]{{cite|doi=10.3389/fphar.2018.00897|anchor=8f63d21f}}. '''Persisting psychosis''' is rare but documented, primarily in people with a personal or family history of psychotic [[glossary:disorder|disorders]]{{cite|doi=10.1177/0269881108093587|anchor=d4c913a0}}. Persistent visual [[glossary:disturbance|disturbances]] — [[effect:geometry]], halos, trails, and [[effect:visual-haze-noise]] — can continue after use ceases, a condition known as [[glossary:hppd]] (HPPD){{cite|doi=10.1037/pha0000597|anchor=00490b9f}}. HPPD has been documented in adolescents{{cite|doi=10.64719/pb.4525|anchor=2effcd2c}} and adults; precise [[glossary:prevalence]] estimates remain unavailable. ====Tolerance & Dependence==== Psilocybin builds [[glossary:tolerance]] rapidly via [[glossary:serotonin]] [[glossary:downregulation]]; consecutive-day dosing produces substantially diminished effects. Clinical protocols space sessions 1–4 weeks apart. [[glossary:cross-tolerance]] with [[substance:lsd]] and other [[glossary:serotonergic-psychedelics]] is established{{cite|doi=10.1177/0269881108093587|anchor=202328e6}}. Psilocybin produces '''no physical dependence''' and '''no clinically recognised withdrawal syndrome'''{{cite|doi=10.1177/0269881108093587|anchor=def6eada}}{{cite|doi=10.1016/j.neuropharm.2017.12.040|anchor=5c11326d}}. A [[glossary:systematic-review]] of psilocybin for [[glossary:substance-use-disorder|substance use disorders]] found no [[glossary:addiction]] signals{{cite|doi=10.1016/j.neubiorev.2025.106163|anchor=ab84a448}}. ====Drug Interactions==== '''MAOIs + psilocybin mushrooms:''' Hypertensive emergency has been documented in [[glossary:case-report|case reports]]{{cite|doi=10.1007/s40263-025-01256-7|anchor=2a849890}}. MAOIs combined with the mushroom's own [[glossary:monoamine-oxidase]]-inhibiting compounds severely impair serotonin breakdown, amplifying serotonergic and cardiovascular effects{{cite|doi=10.1002/chem.201904363|anchor=4941b21b}}. This combination should be avoided. '''SSRIs:''' Long-term SSRI use blunts subjective [[substance_class:psychoactive/psychedelic]] effects. No [[glossary:serotonin-syndrome]] cases from SSRI + psilocybin have been documented in the peer-reviewed literature{{cite|doi=10.1016/j.jpsychires.2024.10.009|anchor=72e260f1}}. '''Lithium:''' Potentially hazardous; proposed mechanisms include serotonergic amplification and pro-convulsant effects{{cite|doi=10.1177/0269881108093587|anchor=c7327e18}}.{{flag|safety-citation-needed}} '''Cannabis:''' May add to [[effect:anxiety]] and paranoia and intensify [[index:effects|subjective effects]]. No specific [[glossary:pharmacokinetic-interaction]] is documented. '''CYP2D6 inhibitors''' (fluoxetine, paroxetine, bupropion, quinidine): may prolong [[substance:psilocin]] exposure by impairing its primary [[glossary:metabolic-pathway]]{{cite|doi=10.3390/pharmaceutics17040411|anchor=4a44be1d}}. ====Contraindications==== '''Absolute contraindications:''' * '''Personal or family history of psychotic disorders''' (schizophrenia, schizoaffective disorder, bipolar I with psychotic features): psilocybin may precipitate or worsen [[glossary:psychosis]]{{cite|doi=10.1177/0269881108093587|anchor=1208d08f}}. * '''Concurrent MAOI use:''' risk of hypertensive emergency{{cite|doi=10.1007/s40263-025-01256-7|anchor=88b3556e}}. '''Relative contraindications:''' * '''Active suicidal ideation:''' exclusion criterion in clinical trials{{cite|doi=10.1056/nejmoa2206443|anchor=ec8f3f3b}}. * '''Cardiovascular disease:''' insufficient safety data{{cite|doi=10.1007/s43440-023-00539-4|anchor=e3e5cedc}}. * '''Concurrent lithium therapy:''' potential [[glossary:seizure]] risk{{cite|doi=10.1177/0269881108093587|anchor=b069e534}}.{{flag|safety-citation-needed}} * '''Hepatic impairment:''' [[glossary:metabolism]] may be slowed, prolonging psilocin exposure. No published data exist. * '''Pregnancy:''' no human safety or teratogenicity data.{{flag|safety-citation-needed}} * '''Adolescents and minors:''' no clinical trials; HPPD documented in a 16-year-old{{cite|doi=10.64719/pb.4525|anchor=44d5f21c}}.

====Toxicity==== Psilocybin has '''low acute physiological toxicity'''. No human fatalities from psilocybin [[glossary:toxicity]] alone are documented in the peer-reviewed literature{{cite|doi=10.1177/0269881108093587|anchor=c29f936d}}. The therapeutic index is extremely high relative to typical human doses{{cite|doi=10.3390/molecules26102948|anchor=1b937650}}. In clinical trials, [[glossary:adverse-events]] are frequent but predominantly transient and self-limiting. The largest Phase 2 trial (233 participants with treatment-resistant [[effect:depression]]) reported adverse events in 77% of participants — most commonly [[effect:headache]], [[effect:nausea]], and [[effect:dizziness]]{{cite|doi=10.1056/nejmoa2206443|anchor=262dad3f}}. A Phase 2 RCT of 25 mg psilocybin for major depressive [[glossary:disorder]] found no serious treatment-emergent adverse events{{cite|doi=10.1001/jama.2023.14530|anchor=bf9a9f42}}. Cardiovascular effects are generally mild and transient, including modest increases in [[glossary:blood-pressure]] and [[glossary:heart-rate]]. Insufficient data exist on psilocybin safety in patients with established cardiovascular disease{{cite|doi=10.1007/s43440-023-00539-4|anchor=f447a4f7}}. Standard workplace urine drug screens do not reliably detect [[substance:psilocin]], with approximately 1.3% cross-reactivity on [[substance:amphetamine]]/[[substance:methamphetamine]] [[glossary:assay|assays]]{{cite|doi=10.1016/bs.acc.2016.07.004|anchor=3c4bc6a4}}{{cite|pubmed=16839473|anchor=41502232}}. Confirmatory GC-MS or LC-MS/MS is required for definitive identification. Psilocin is detectable in urine for approximately 24–72 hours after [[glossary:ingestion]]. '''Contaminant and adulterant risks:''' Wild-harvested mushrooms carry the primary danger of '''misidentification with hepatotoxic species''', particularly ''Galerina marginata'' (amatoxin-containing), which can be fatal{{cite|doi=10.3389/ffgc.2022.813998|anchor=8c36764d}}. Commercially obtained products sold as psilocybin may be adulterated with [[glossary:synthetic]] substances — NBOMe-series compounds have been detected in pressed tablets and powders. Ehrlich [[glossary:reagent-kit|reagent testing]] produces a purple/violet reaction confirming [[substance_class:chemical/indole]] presence but does not rule out all synthetic imposters; definitive identification requires GC-MS or LC-MS/MS{{cite|doi=10.1016/bs.acc.2016.07.004|anchor=b565efcf}}. Cultivated mushrooms are susceptible to mould [[glossary:contamination]] (''Trichoderma'' spp., cobweb mould), implying potential mycotoxin exposure.{{flag|safety-citation-needed}} No ISO/IEC-accredited lab testing programs or Certificate of Analysis requirements currently apply to psilocybin mushroom products in any jurisdiction with regulated access. ====Psychological Risks==== The most common adverse psychological event is the '''acute anxiety reaction''' — an overwhelming experience characterised by intense [[effect:anxiety]], fear, [[effect:paranoia]], panic, and dysphoric [[effect:confusion]]{{cite|doi=10.1177/0269881108093587|anchor=df2a1330}}. This risk is dose-dependent and context-dependent, mitigated by appropriate set, setting, and interpersonal support{{cite|doi=10.3389/fphar.2018.00897|anchor=94640088}}. '''Persisting psychosis''' is rare but documented, primarily in individuals with personal or family history of psychotic disorders. This is the principal screening [[glossary:contraindication]] in all clinical research protocols{{cite|doi=10.1177/0269881108093587|anchor=5bf06ed8}}. '''Hallucinogen persisting perception disorder (HPPD)''' involves persistent visual [[glossary:disturbance|disturbances]] — [[effect:geometry]], halos, trails, [[effect:visual-haze-noise]] — continuing after use ceases. Psilocybin and [[substance:lsd]] are the most commonly reported precipitants{{cite|doi=10.1037/pha0000597|anchor=8e8a1b88}}. [[glossary:hppd]] has been documented in adolescents{{cite|doi=10.64719/pb.4525|anchor=0dbd535a}} and adults; precise [[glossary:prevalence]] estimates remain unavailable. ====Tolerance & Dependence==== Psilocybin produces '''rapid tachyphylaxis''' via [[glossary:5-ht2a]] [[glossary:downregulation]]. Consecutive-day dosing produces substantially diminished effects; clinical protocols space sessions by 1–4 weeks. [[glossary:cross-tolerance]] with LSD and other [[glossary:serotonergic-psychedelics]] is established{{cite|doi=10.1177/0269881108093587|anchor=1761fee0}}. Psilocybin produces '''no physical dependence''' and '''no clinically recognised withdrawal syndrome'''{{cite|doi=10.1177/0269881108093587|anchor=13bf7ffd}}{{cite|doi=10.1016/j.neuropharm.2017.12.040|anchor=5b39ecf4}}. The DSM-5 does not include a [[substance_class:psychoactive/hallucinogen]] [[glossary:withdrawal]]. A [[glossary:systematic-review]] of psilocybin for [[glossary:substance-use-disorder|substance use disorders]] found no addiction signals{{cite|doi=10.1016/j.neubiorev.2025.106163|anchor=da106e46}}. ====Drug Interactions==== '''MAOI + psilocybin mushrooms:''' Hypertensive emergency has been documented in [[glossary:case-report|case reports]]{{cite|doi=10.1007/s40263-025-01256-7|anchor=02cbff4f}}. Exogenous MAOIs combined with endogenous β-carboline [[substance_class:pharmacological/monoamine-oxidase-inhibitor|monoamine oxidase inhibitors]] in the mushroom matrix{{cite|doi=10.1002/chem.201904363|anchor=1e450821}} severely impair [[glossary:serotonin]] [[glossary:metabolism]], potentiating both serotonergic and [[glossary:sympathomimetic|sympathomimetic effects]]. This combination should be avoided. '''SSRIs:''' Long-term SSRI use is associated with blunted subjective [[substance_class:psychoactive/psychedelic]] effects, likely via 5-HT₂A receptor downregulation. A post-hoc analysis found that [[substance_class:psychoactive/antidepressant]] [[glossary:discontinuation]] prior to psilocybin did not significantly affect clinical outcomes in treatment-resistant depression{{cite|doi=10.1016/j.jpsychires.2024.10.009|anchor=8378f1d9}}. No [[glossary:serotonin-syndrome]] cases from SSRI + psilocybin have been documented in the peer-reviewed literature. '''Lithium:''' The [[substance:lithium]] + psilocybin combination is flagged as potentially hazardous, with proposed mechanisms including serotonergic amplification and lithium's pro-convulsant effects{{cite|doi=10.1177/0269881108093587|anchor=00be7e86}}. {{flag|safety-citation-needed}} '''Cannabis:''' Additive effects on anxiety and paranoia have been reported. Co-administration may intensify [[index:effects|subjective effects]]. No specific [[glossary:pharmacokinetic-interaction]] is documented. '''CYP2D6 inhibitors:''' Drugs inhibiting [[glossary:cyp2d6]] (fluoxetine, paroxetine, bupropion, quinidine) may prolong psilocin exposure by impairing its primary [[glossary:metabolic-pathway]]{{cite|doi=10.3390/pharmaceutics17040411|anchor=6824e11b}}. ====Contraindications==== '''Absolute contraindications:''' * '''Personal or family history of psychotic disorders''' (schizophrenia, schizoaffective disorder, bipolar I with psychotic features): psilocybin may precipitate or exacerbate [[glossary:psychosis]]. This is the primary exclusion criterion in all clinical research protocols{{cite|doi=10.1177/0269881108093587|anchor=740fd5a2}}. * '''Concurrent MAOI use:''' risk of hypertensive emergency{{cite|doi=10.1007/s40263-025-01256-7|anchor=c5701882}}. '''Relative contraindications:''' * '''Active suicidal ideation:''' exclusion criterion in clinical trials{{cite|doi=10.1056/nejmoa2206443|anchor=431a8d93}}. * '''Cardiovascular disease:''' insufficient safety data in patients with established cardiovascular disease{{cite|doi=10.1007/s43440-023-00539-4|anchor=ea21bacf}}. * '''Concurrent lithium therapy:''' potential [[glossary:seizure]] risk{{cite|doi=10.1177/0269881108093587|anchor=bb46e553}}. {{flag|safety-citation-needed}} * '''Hepatic impairment:''' CYP2D6/[[glossary:cyp3a4]] metabolism may be impaired, prolonging psilocin exposure. No published data exist. * '''Pregnancy:''' no human safety or teratogenicity data. {{flag|safety-citation-needed}} * '''Adolescent and pediatric populations:''' no clinical trials in minors; HPPD documented in a 16-year-old{{cite|doi=10.64719/pb.4525|anchor=3d068bf5}}.

====Dried whole mushrooms (oral)==== '''Dried whole mushrooms''' are the most common preparation. Fruiting bodies are dehydrated and consumed directly or mixed with food. Threshold: 0.25–0.5 g; common: 1–2.5 g; strong: 3–5 g. Onset: 20–60 minutes. Duration: 4–6 hours. [[effect:nausea]] is frequent at onset, particularly on a full stomach. [[glossary:potency]] varies 2–4-fold between individual fruiting bodies{{cite|doi=10.3390/ijms232214068|anchor=4de0ec75}}, making precise dosing difficult with uncharacterised material. ====Mushroom tea (oral)==== '''Mushroom tea''' is made by steeping chopped or ground dried mushrooms in hot (not boiling) water for 10–20 minutes, then straining. [[glossary:dose-range|Dose ranges]] are equivalent to dried whole mushrooms by starting weight. Onset is faster (15–30 minutes). Duration may be slightly shorter (3–5 hours). Straining removes chitin and reduces nausea for many users. ====Lemon tek (oral)==== '''Lemon tek''' involves soaking finely ground dried mushroom material in lemon or lime juice for 15–20 minutes before consuming the liquid. The acidic environment accelerates conversion of psilocybin to [[substance:psilocin]], producing faster onset (10–20 minutes), a more compressed and often more intense experience, and shorter total duration (3–4 hours). Dose ranges by weight are equivalent to dried mushrooms; the compressed timeline raises the risk of overwhelming [[glossary:intensity]] at usual dose amounts. ====Capsules (oral)==== '''Capsules''' contain measured amounts of dried, ground mushroom material, offering more consistent dosing than whole fruiting bodies. Microdose capsules typically contain 0.05–0.3 g, intended for sub-perceptual effects on a schedule. Full-dose capsules follow the same dose ranges as dried whole mushrooms. Onset and duration are comparable to dried mushroom [[glossary:ingestion]]. ====Fresh mushrooms (oral)==== '''Fresh mushrooms''' contain approximately 90% water by weight — roughly 10 g fresh corresponds to 1 g dried. Onset and duration are similar to dried preparations. Fresh material degrades rapidly without refrigeration. Per-preparation dose tiers, timelines, and [[glossary:bioavailability]] data are in the Dose · by preparation card on this page.

====Dried whole mushrooms (oral)==== '''Dried whole mushrooms''' are the most common preparation. Fruiting bodies are dehydrated and consumed directly or mixed with food. Threshold: 0.25–0.5 g dried; common: 1–2.5 g dried; strong: 3–5 g dried. Onset: 20–60 minutes. Duration: 4–6 hours. [[effect:nausea]] is frequent at onset, particularly on a full stomach. [[glossary:potency]] varies 2–4-fold between individual fruiting bodies{{cite|doi=10.3390/ijms232214068|anchor=9efdf23c}}, making precise dosing difficult with uncharacterised material. ====Mushroom tea (oral)==== '''Mushroom tea''' is prepared by steeping chopped or ground dried mushrooms in hot (not boiling) water for 10–20 minutes, then straining. [[glossary:dose-range|Dose ranges]] are equivalent to dried whole mushrooms by weight of starting material. Onset is typically faster (15–30 minutes) due to aqueous extraction of psilocybin. Duration may be slightly shorter (3–5 hours). The straining step reduces chitin-related nausea for many users. ====Lemon tek (oral)==== '''Lemon tek''' involves soaking finely ground dried mushroom material in lemon or lime juice for 15–20 minutes before consumption. The acidic environment is reported to accelerate dephosphorylation of psilocybin to [[substance:psilocin]], producing a faster onset (10–20 minutes) and a more compressed, often more intense experience with a shorter total duration (3–4 hours). Dose ranges by weight are equivalent to dried mushrooms, but the compressed timeline increases the risk of overwhelming [[glossary:intensity]] — starting at the lower end of one's usual dose range is advisable. ====Capsules and microdose preparations (oral)==== '''Capsules''' contain measured amounts of dried, ground mushroom material, offering more consistent dosing than whole fruiting bodies. Microdose capsules typically contain 0.05–0.3 g dried material, intended for sub-perceptual effects taken on a schedule (e.g., one day on, two days off). Full-dose capsules follow the same dose ranges as dried whole mushrooms. Onset and duration are comparable to dried mushroom [[glossary:ingestion]]. ====Fresh mushrooms (oral)==== '''Fresh mushrooms''' contain approximately 90% water by weight, so roughly 10 g fresh corresponds to 1 g dried. They are consumed directly or blended into smoothies. Onset and duration are similar to dried preparations. Fresh material degrades rapidly if not refrigerated. Per-preparation dose tiers, timelines, and [[glossary:bioavailability]] data are in the Dose · by preparation card on this page.

===Forms & Identification=== Lab testing is the only reliable method to confirm that a mushroom product contains psilocybin and is free of [[glossary:contamination|contaminants]] or [[glossary:adulterant|adulterants]]. Ehrlich [[glossary:reagent-kit|reagent testing]] confirms [[substance_class:chemical/indole-alkaloid]] presence (purple/violet reaction) but cannot distinguish psilocybin from all [[glossary:synthetic]] [[substance_class:chemical/indole|indoles]] — a positive result is necessary but not sufficient. For whole dried mushrooms, the bluing reaction on damaged tissue and a purplish-black spore print are the most reliable field indicators of ''Psilocybe'' species. [[glossary:misidentification]] with ''Galerina marginata'' — rusty-brown spore print, lethal amatoxin content — is the primary physical safety risk of wild foraging. ===Set & Setting=== Set (mindset) and setting (environment) influence psilocybin experiences as powerfully as dose itself{{cite|doi=10.3389/fphar.2018.00897|anchor=85c26d65}}. A familiar, physically safe, comfortable environment with minimal unexpected [[effect:stimulation]] reduces risk. Use during periods of [[glossary:distress|acute psychological distress]], unresolved grief, or high [[effect:anxiety]] elevates the risk of [[glossary:difficult-experience|difficult experiences]]. A trusted, sober companion ("[[glossary:sitter|trip sitter]]") substantially reduces risk, especially for inexperienced users or higher doses. The sitter's role is to provide calm [[glossary:reassurance]], not to direct the experience. Clinical protocols universally include trained support personnel for this reason. ===Guidelines=== {{Guideline}} ===Practical guidance=== * '''Start low.''' Begin with 0.5–1 g dried mushroom material for a first experience. Increase only after assessing individual [[glossary:sensitivity]]. * '''Weigh the dose.''' Use a digital scale accurate to 0.1 g. Do not estimate by visual size — [[glossary:potency]] varies 2–4-fold between individual fruiting bodies. * '''Allow time.''' Onset takes 20–60 minutes (faster with tea or lemon tek). Do not [[glossary:redose]] before 90 minutes. * '''Eat lightly beforehand.''' A light meal 2–3 hours before reduces [[effect:nausea]] without significantly delaying onset. * '''Prepare the environment.''' Remove hazards. Have water, comfortable seating, blankets, calming music, and a phone accessible. * '''Plan the time.''' Block 6–8 hours with no obligations. Do not drive or operate machinery. * '''Avoid dangerous combinations.''' Do not combine with MAOIs, [[substance:lithium]], or [[substance:cannabis]] (especially for inexperienced users). Review [[glossary:drug-interaction|Drug Interactions]] in the Safety section. * '''Test the material.''' Use Ehrlich reagent at minimum. For commercial products, request or verify Certificate of Analysis where available. {{/Guideline}} ===Emergency Response=== {{Emergency}} ===Recognising and responding to a crisis=== '''Recognise an emergency:''' * Severe, escalating panic or [[effect:paranoia]] unresponsive to reassurance * [[glossary:psychosis|Psychotic symptoms]]: [[effect:delusions]], loss of contact with reality, [[glossary:self-harm]] impulses * [[glossary:seizure|Seizures]] or [[glossary:loss-of-consciousness]] * [[glossary:chest-pain]] or difficulty breathing * Suicidal statements or actions '''Immediate steps:''' * 1. Stay with the person. Do not leave them alone. * 2. Speak calmly and simply: "You are safe. You took a mushroom. The effects are temporary." * 3. Move them to a quiet, low-stimulation space if possible. * 4. If they are overheating, cool them with water and airflow. * 5. Call emergency services (911 / 112 / local equivalent) if: seizures occur, breathing is compromised, psychotic symptoms are severe, or the person is at risk of harming themselves or others. '''What to tell the dispatcher:''' * "They [[glossary:ingestion|ingested]] [[substance:psilocybin-mushrooms]]" — name the substance. * Approximate amount and time of ingestion. * Current symptoms. * [[glossary:good-samaritan-law|Good Samaritan laws]] in many jurisdictions protect callers reporting drug emergencies from [[glossary:prosecution]]. There is no pharmacological reversal agent for psilocybin. [[substance_class:chemical/benzodiazepine|Benzodiazepines]] may be administered by medical professionals to manage severe anxiety or [[glossary:agitation]]. Time is the primary resolution — acute effects resolve within 4–8 hours. {{/Emergency}} ===Aftercare & Integration=== {{Aftercare}} ===Post-experience processing=== The hours and days following a psilocybin experience often include emotional sensitivity, [[glossary:fatigue]], and a reflective mood. This is normal and typically resolves within 24–48 hours. * '''Hydrate and eat.''' Appetite may be suppressed during the experience. Rehydrate and consume a balanced meal afterward. * '''Rest.''' Sleep may be disrupted the night of the experience. Allow extra rest the following day. * '''Reflect, don't react.''' Significant experiences may provoke strong feelings or [[glossary:insight|insights]]. Journaling or talking with a trusted person helps [[glossary:integration]]. Avoid major life decisions in the immediate aftermath. * '''Monitor mood.''' If persistent anxiety, [[effect:depersonalization|depersonalisation]], or visual [[glossary:disturbance|disturbances]] arise, consult a healthcare professional. {{/Aftercare}} ===Recovery & Support=== {{Recovery}} ===Cessation and support resources=== Psilocybin does not produce [[glossary:physical-dependence]] or [[glossary:withdrawal]]. Patterns of repeated use that interfere with daily functioning warrant attention and support. * '''SAMHSA National Helpline:''' 1-800-662-4357 (US) — free, confidential, 24/7 [[glossary:referral]] service. * '''Fireside Project:''' 62-FIRESIDE (623-473-7433) — [[substance_class:psychoactive/psychedelic]] [[glossary:peer-support]] line. * '''Crisis Text Line:''' Text HOME to 741741 (US). * '''Integration therapists:''' Directories at MAPS (maps.org) and Psychedelic.Support list [[glossary:therapist|therapists]] experienced in psychedelic integration. * '''Tolerance management:''' Psilocybin's rapid [[glossary:tolerance]] ([[glossary:full-reset]] in approximately 10–14 days) naturally limits frequent use. If using more often than every two weeks, consider whether the pattern serves a constructive purpose. {{/Recovery}}

===Forms & Identification=== Lab testing is the only reliable method to confirm that a mushroom product contains psilocybin and is free of [[glossary:contamination|contaminants]] or [[glossary:adulterant|adulterants]]. Ehrlich [[glossary:reagent-kit|reagent testing]] confirms [[substance_class:chemical/indole-alkaloid]] presence (purple/violet reaction) but cannot distinguish psilocybin from all [[glossary:synthetic]] [[substance_class:chemical/indole|indoles]] — a positive Ehrlich result is necessary but not sufficient. For pressed tablets, capsules, or powders sold as "psilocybin," reagent testing is especially important: NBOMe-series compounds and other [[glossary:novel-psychoactive-substance|research chemicals]] have been detected in products marketed as [[substance:psilocybin-mushrooms]]. For whole dried mushrooms, identification skill matters. The bluing reaction on damaged tissue and a purplish-black spore print are the most reliable field indicators of ''Psilocybe'' species. [[glossary:misidentification]] with ''Galerina marginata'' (amatoxin-containing, rusty-brown spore print) is the primary physical safety risk of wild foraging. When in doubt, do not consume. ===Set & Setting=== Set (mindset) and setting (environment) influence psilocybin experiences as powerfully as dose itself. Choose a familiar, physically safe, comfortable environment with minimal unexpected [[effect:stimulation]]. Avoid use during periods of [[glossary:distress|acute psychological distress]], unresolved grief, or high [[effect:anxiety]] — these states elevate the risk of [[glossary:difficult-experience|difficult experiences]]. A trusted, sober companion ("[[glossary:sitter|trip sitter]]") is strongly recommended, especially for inexperienced users or higher doses. The sitter's role is to provide calm [[glossary:reassurance]], not to direct the experience. Clinical protocols universally include trained support personnel for this reason. ===Guidelines=== {{Guideline}} ===Practical guidance=== * '''Start low.''' Begin with 0.5–1 g dried mushroom material for a first experience. Increase only after assessing individual [[glossary:sensitivity]]. * '''Weigh your dose.''' Use a digital scale accurate to 0.1 g. Do not estimate by visual size — [[glossary:potency]] varies 2–4-fold between individual fruiting bodies. * '''Allow time.''' Onset takes 20–60 minutes (faster with tea or lemon tek). Do not [[glossary:redose]] before 90 minutes. * '''Eat lightly beforehand.''' A light meal 2–3 hours before reduces [[effect:nausea]] without significantly delaying onset. * '''Prepare your environment.''' Remove hazards. Have water, comfortable seating, blankets, calming music, and a phone accessible. * '''Plan your time.''' Block 6–8 hours with no obligations. Do not drive or operate machinery. * '''Avoid dangerous combinations.''' Do not combine with MAOIs, [[substance:lithium]], or [[substance:cannabis]] (especially for inexperienced users). Review [[glossary:drug-interaction|Drug Interactions]] in the Safety section. * '''Test your material.''' Use Ehrlich reagent at minimum. For commercial products, request or verify Certificate of Analysis where available. {{/Guideline}} ===Emergency Response=== {{Emergency}} ===Recognising and responding to a crisis=== '''Recognise an emergency:''' * Severe, escalating panic or [[effect:paranoia]] unresponsive to reassurance * [[glossary:psychosis|Psychotic symptoms]]: [[effect:delusions]], loss of contact with reality, [[glossary:self-harm]] impulses * [[glossary:seizure|Seizures]] or [[glossary:loss-of-consciousness]] * [[glossary:chest-pain]] or difficulty breathing * Suicidal statements or actions '''Immediate steps:''' * 1. Stay with the person. Do not leave them alone. * 2. Speak calmly and simply: "You are safe. You took a mushroom. The effects are temporary." * 3. Move them to a quiet, low-stimulation space if possible. * 4. If they are overheating, cool them with water and airflow. * 5. Call emergency services (911 / 112 / local equivalent) if: seizures occur, breathing is compromised, psychotic symptoms are severe, or the person is at risk of harming themselves or others. '''What to tell the dispatcher:''' * "They [[glossary:ingestion|ingested]] psilocybin mushrooms" — name the substance. * Approximate amount and time of ingestion. * Current symptoms. * [[glossary:good-samaritan-law|Good Samaritan laws]] in many jurisdictions protect callers reporting drug emergencies from [[glossary:prosecution]]. There is no pharmacological reversal agent for psilocybin. [[substance_class:chemical/benzodiazepine|Benzodiazepines]] may be administered by medical professionals to manage severe anxiety or [[glossary:agitation]]. Time is the primary resolution — acute effects resolve within 4–8 hours. {{/Emergency}} ===Aftercare & Integration=== {{Aftercare}} ===Post-experience processing=== The hours and days following a psilocybin experience often include emotional sensitivity, [[glossary:fatigue]], and a reflective or contemplative mood. This is normal and typically resolves within 24–48 hours. * '''Hydrate and eat.''' Appetite may be suppressed during the experience. Rehydrate and consume a balanced meal afterward. * '''Rest.''' Sleep may be disrupted the night of the experience. Allow extra rest the following day. * '''Reflect, don't react.''' Significant experiences may provoke strong feelings or [[glossary:insight|insights]]. Journaling or talking with a trusted person helps [[glossary:integration]]. Avoid making major life decisions in the immediate aftermath. * '''Monitor mood.''' Most users report positive [[glossary:aftereffect|aftereffects]] for days to weeks. If persistent anxiety, [[effect:depersonalization|depersonalisation]], or visual [[glossary:disturbance|disturbances]] arise, consult a healthcare professional. {{/Aftercare}} ===Recovery & Support=== {{Recovery}} ===Cessation and support resources=== Psilocybin does not produce [[glossary:physical-dependence]] or [[glossary:withdrawal]]. However, patterns of repeated use that interfere with daily functioning warrant attention and support. * '''SAMHSA National Helpline:''' 1-800-662-4357 (US) — free, confidential, 24/7 [[glossary:referral]] service. * '''Fireside Project:''' 62-FIRESIDE (623-473-7433) — [[substance_class:psychoactive/psychedelic]] [[glossary:peer-support]] line. * '''Crisis Text Line:''' Text HOME to 741741 (US). * '''Integration therapists:''' Directories at MAPS (maps.org) and Psychedelic.Support list [[glossary:therapist|therapists]] experienced in psychedelic integration. * '''Tolerance management:''' Psilocybin's rapid [[glossary:tolerance]] ([[glossary:full-reset]] in approximately 10–14 days) naturally limits frequent use. If using more often than every two weeks, consider whether the pattern serves a constructive purpose. {{/Recovery}}

===Receptor pharmacology=== [[substance:psilocin]], the [[glossary:active-metabolite]] of psilocybin, acts primarily as a '''partial agonist at 5-HT₂A serotonin receptors''' — particularly in pyramidal [[glossary:neuron|neurons]] of the [[glossary:prefrontal-cortex]] — which constitutes the principal mechanism underlying [[substance_class:psychoactive/psychedelic]] effects in humans{{cite|doi=10.1016/j.tips.2025.08.012|anchor=542b7494}}. Additional [[glossary:receptor-binding|receptor interactions]] include: * '''5-HT₁A''' agonism — contributes to long-term synaptic [[effect:depression]] via enhanced GABAergic tone; recent evidence demonstrates [[glossary:5-ht1a]]-mediated, [[glossary:5-ht2a]]-independent long-term depression in the prelimbic [[glossary:cortex]]{{cite|doi=10.1016/j.neuropharm.2026.110854|anchor=5b1ee832}}. * '''5-HT₂C''' agonism — contributes to mood regulation and anxiogenic effects at higher doses. * '''TrkB''' ([[glossary:bdnf]] [[glossary:receptor]]) — psilocin activates [[glossary:trkb]] independently of 5-HT₂A, potentially explaining sustained neuroplastic effects that persist beyond acute pharmacological activity{{cite|doi=10.1016/j.tips.2025.08.012|anchor=f09c0015}}. * '''5-HT₂B''' — at sub-psychedelic doses, psilocin demonstrates metabolic effects (weight and liver steatosis reduction in mice) via hepatic serotonin₂B [[glossary:antagonism]], a mechanism distinct from its central psychedelic activity{{cite|doi=10.1016/j.phrs.2025.108080|anchor=97111487}}. For detailed receptor binding affinities, see the Psilocin compound page. ===Network-level mechanisms=== The REBUS model (Relaxed Beliefs Under Psychedelics) provides the dominant theoretical framework: psilocin relaxes high-level cortical priors — top-down predictions — allowing greater influence of bottom-up sensory information and increasing entropy in cortical signal{{cite|doi=10.1124/pr.118.017160|anchor=741b78b3}}. Siegel et al. (2024) tracked individual brain changes using longitudinal precision fMRI (18 MRI visits per participant). A single 25 mg dose of psilocybin caused greater than 3-fold more functional connectivity [[glossary:disruption]] than [[substance:methylphenidate]], with effects strongest in the '''default mode network (DMN)'''. A persistent decrease in [[glossary:hippocampus|hippocampal]]-[[glossary:default-mode-network]] connectivity lasted for three weeks post-session — hypothesized as a neuroanatomical correlate of psilocybin's pro-[[glossary:neuroplasticity|plasticity]] and [[glossary:therapeutic-effect|therapeutic effects]]{{cite|doi=10.1038/s41586-024-07624-5|anchor=b8e24ea7}}. ===Pharmacokinetics=== A [[glossary:systematic-review]] of 14 pharmacokinetic studies summarizes the oral kinetics of [[glossary:synthetic]] psilocybin{{cite|doi=10.3390/pharmaceutics17040411|anchor=c6da9e1e}}: * Psilocybin is rapidly dephosphorylated to psilocin by intestinal alkaline phosphatase and tissue phosphatases. * '''Psilocin Tmax:''' 1.8–4 hours (oral). * '''Cmax:''' 8.2 ± 2.8 ng/mL at oral doses of 10–20 mg psilocybin{{cite|pubmed=9204776|anchor=8249e530}}. * '''Oral bioavailability:''' 52.7 ± 20%. * '''Volume of distribution:''' 277–1,016 L (extensive tissue distribution). * '''Elimination half-life:''' 1.5–4 hours for psilocin. * '''Metabolism:''' Primarily [[glossary:cyp2d6]] and [[glossary:cyp3a4]]; secondary [[glossary:mao-a]]. Primary [[glossary:metabolite|metabolites]]: 4-hydroxyindole-3-acetic acid (4-HIAA) and 4-hydroxytryptophol. [[glossary:intravenous]] administration of 1 mg psilocybin produces psilocin cmax of 12.9 ± 5.6 ng/mL at 1.9 ± 1.0 minutes, confirming rapid dephosphorylation in blood{{cite|pubmed=9204776|anchor=74b9f72e}}. [[glossary:poor-metabolizer|CYP2D6 poor metabolizers]] may experience prolonged or intensified psilocin exposure. CYP2D6 [[glossary:inhibitor|inhibitors]] (e.g., paroxetine, fluoxetine) may alter psilocin kinetics — indirect evidence from [[substance:lsd]] [[glossary:pharmacokinetics]] shows paroxetine increases LSD exposure 1.4–1.5-fold; a comparable mechanism is plausible for psilocin but has not been directly demonstrated.{{flag|citation-needed}} The [[glossary:endogenous]] β-carbolines in ''P. cubensis'' mushrooms inhibit MAO-A, which normally participates in psilocin [[glossary:degradation]]. This may extend the effective [[glossary:half-life]] of psilocin from whole-mushroom preparations relative to synthetic psilocybin{{cite|doi=10.1002/chem.201904363|anchor=2e721f54}}. No human pharmacokinetic study has quantified this difference. ===Open questions=== * Whole-mushroom pharmacokinetics versus synthetic psilocybin in humans remain uncharacterized. * The specific contribution of CYP2D6 [[glossary:genetic-polymorphism|polymorphisms]] to interindividual variability in psilocybin response has not been established in a dedicated [[glossary:genotype]]-stratified study. * Whether endogenous β-carbolines in mushroom preparations alter clinical outcomes relative to synthetic psilocybin is unknown.

Psilocybin and [[substance:psilocin]] are [[glossary:schedule-i]] substances under the 1971 UN [[glossary:convention-on-psychotropic-substances]], though [[substance:psilocybin-mushrooms]] themselves were not explicitly listed in the Convention text{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=8ebce992}}. This ambiguity has allowed several jurisdictions to permit whole-mushroom or truffle use while formally prohibiting the isolated compounds. The legal landscape is shifting rapidly: regulated therapeutic access now exists in Oregon, Australia, and (via exemption) Canada, while federal [[glossary:prohibition]] continues in the United States, the United Kingdom, and most of Europe.

Jurisdiction	Status	Notes
United States (federal)	Schedule I	Psilocybin and psilocin are Schedule I under the Controlled Substances Act (1970). DEA forwarded a rescheduling petition (Schedule I to II) in August 2025; outcome pending{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=c885c9a4}}.
Oregon (US)	Regulated therapeutic access	Measure 109 (2020): licensed, supervised psilocybin services. First centres opened 2023. Unregulated personal use remains illegal.
Colorado (US)	Decriminalised + regulated healing centres	Proposition 122 (2022): personal use, possession, cultivation, and gifting decriminalised for adults 21+. Regulated healing centres under development.
Other US cities	Local decriminalisation	Oakland CA, Santa Cruz CA, Ann Arbor MI, Seattle WA, Detroit MI, Northampton MA, and others have passed deprioritisation or decriminalisation measures.
Canada	Schedule III	Health Canada has authorised access for palliative care and therapist training via Section 56 exemptions and the Special Access Program.{{flag|citation-needed}}
United Kingdom	Class A	Most severe penalty classification under the Misuse of Drugs Act (1971). Research requires Home Office licence{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=a006ae16}}.
Netherlands	Mushrooms banned (2008); truffles legal	Psilocybin mushrooms prohibited since 2008. Psilocybin-containing sclerotia (magic truffles) remain legal and sold in licensed smart shops.{{flag|citation-needed}}
Germany	Controlled (BtMG)	Schedule I analogue. Compassionate-use pathways for TRD have been authorised at select institutions.{{flag|citation-needed}}
Australia	Schedule 8 — Controlled Medicine	Rescheduled from Schedule 9 (effective 1 July 2023) for treatment-resistant depression only. Must be prescribed by a TGA-authorised psychiatrist; administered in a controlled medical setting with psychotherapy{{cite|name=tga-rescheduling-2023|type=book|author=Therapeutic Goods Administration|year=2023|title=Change of classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists|anchor=95dd2cbd}}.
Jamaica	Not scheduled	Psilocybin mushrooms are not prohibited under Jamaican law. Retreat centres operate legally.
Brazil	Not explicitly scheduled	Psilocybin is not listed as a controlled substance. Legal ambiguity exists in practice.

The distinction between scheduled compounds (psilocybin, psilocin) and [[glossary:unscheduled]] biological material (mushrooms, truffles) under the 1971 UN Convention creates the legal space used by jurisdictions such as the Netherlands and Jamaica. National implementations vary in whether compound scheduling extends to the biological source organism or is restricted to isolated substances.

Psilocybin and [[substance:psilocin]] are scheduled under the 1971 UN [[glossary:convention-on-psychotropic-substances]] — though [[substance:psilocybin-mushrooms]] themselves were not explicitly named in the treaty{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=d131d04b}}. This ambiguity has allowed some jurisdictions to permit whole-mushroom or truffle use while formally prohibiting the isolated compounds. In the United States, psilocybin and psilocin are [[glossary:schedule-i]] under federal law, with a rescheduling petition pending as of 2025; Oregon operates a regulated therapeutic access framework (first centres opened 2023); Colorado has decriminalised personal use for adults; and several cities — including Oakland, Santa Cruz, Ann Arbor, and Seattle — have passed local deprioritisation measures{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=35ba08ab}}. In the United Kingdom, psilocybin is [[glossary:class-a]] — the most severe penalty category{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=8120a1a4}}. Australia rescheduled psilocybin in 2023 to permit prescribing by authorised psychiatrists for treatment-resistant [[effect:depression]]{{cite|name=tga-rescheduling-2023|type=book|author=Therapeutic Goods Administration|year=2023|title=Change of classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists|anchor=9c5b6ef2}}. The Netherlands prohibits dried mushrooms but permits psilocybin-containing truffles; Canada permits access via exemption for palliative care and [[glossary:therapist]] training. The legal landscape is shifting rapidly across many jurisdictions. {{Warning}} Legal status changes frequently. This overview reflects the status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information. {{/Warning}}

The experiential character of ''Psilocybe cubensis'' is shaped primarily by dose, preparation method, and the psychosocial context of consumption — [[glossary:set-and-setting]] exert an influence on experience quality that rivals or exceeds that of dose alone{{cite|doi=10.3389/fphar.2018.00897|anchor=82b702fc}}. The mushroom matrix delivers a cocktail of [[substance_class:chemical/tryptamine]] alkaloids alongside β-carboline [[substance_class:pharmacological/monoamine-oxidase-inhibitor|monoamine oxidase inhibitors]], producing a pharmacological milieu distinct from [[glossary:synthetic]] psilocybin; whether this translates to a meaningfully different subjective profile in humans remains an open question supported only by preclinical evidence{{cite|doi=10.1038/s41380-024-02477-w|anchor=c60c8069}}. Batch-to-batch alkaloid variability introduces an irreducible source of dosing imprecision absent from [[glossary:pharmaceutical-grade|pharmaceutical-grade]] psilocybin. Relative to [[substance:lsd]] — the serotonergic [[substance_class:psychoactive/psychedelic]] most frequently compared by users — ''P. cubensis'' produces a shorter experience (4–8 hours versus 8–12 hours) with effects generally described as more somatically grounded and emotionally introspective. Compared to synthetic psilocybin administered in clinical settings, whole-mushroom preparations introduce the additional variable of multi-alkaloid composition and uncontrolled [[glossary:potency]], which may contribute to the wider range of reported subjective intensities at ostensibly equivalent doses.

===Toxicity=== Psilocybin is widely characterized as having '''low acute physiological toxicity'''. No human fatalities from psilocybin [[glossary:toxicity]] alone have been documented in the peer-reviewed literature{{cite|doi=10.1177/0269881108093587|anchor=f7563e01}}. The estimated oral [[glossary:lethal-dose|LD₅₀]] in rats is approximately 280 mg/kg{{cite|doi=10.3390/molecules26102948|anchor=49507c5b}}, placing the therapeutic index extremely high relative to typical human doses of 0.1–0.5 mg/kg. In controlled clinical settings, [[glossary:adverse-events]] are frequent but predominantly transient and self-limiting. The largest Phase 2 trial (233 participants with treatment-resistant [[effect:depression]]) reported adverse events in 77% of participants; the most common were [[effect:headache]], [[effect:nausea]], and [[effect:dizziness]]{{cite|doi=10.1056/nejmoa2206443|anchor=730609d7}}. A Phase 2 RCT of 25 mg psilocybin for major depressive [[glossary:disorder]] reported no serious treatment-emergent adverse events but a higher overall rate of adverse events versus niacin placebo{{cite|doi=10.1001/jama.2023.14530|anchor=9a98deb2}}. Cardiovascular effects are generally transient: [[glossary:5-ht2a]]/₂B agonism produces [[glossary:sympathomimetic]] responses including mild increases in [[glossary:blood-pressure]] and [[glossary:heart-rate]]. A molecularly confirmed [[glossary:case-series]] of ''Psilocybe keralensis'' poisoning documented myocardial injury{{cite|doi=10.1080/15563650.2025.2552438|anchor=d4c5ebe1}}, though this species differs from ''P. cubensis''. Insufficient data exist on psilocybin safety in patients with established cardiovascular disease{{cite|doi=10.1007/s43440-023-00539-4|anchor=98939af0}}. Standard workplace immunoassay urine drug screens do not reliably detect [[substance:psilocin]], with cross-reactivity of approximately 1.3% on [[substance:amphetamine]]/[[substance:methamphetamine]] [[glossary:assay|assays]]{{cite|doi=10.1016/bs.acc.2016.07.004|anchor=aa8d1fa3}}{{cite|pubmed=16839473|anchor=a7bc8968}}. Confirmatory GC-MS or LC-MS/MS is required for definitive identification. Psilocin is detectable in urine for approximately 24–72 hours after [[glossary:ingestion]], though the precise detection window varies with dose and analytical [[glossary:sensitivity]]. ====Contaminant and adulterant risks==== Wild-harvested [[substance:psilocybin-mushrooms]] carry the primary physical safety risk of '''misidentification with hepatotoxic species''', particularly ''Galerina marginata'' (amatoxin-containing), which can be fatal{{cite|doi=10.3389/ffgc.2022.813998|anchor=8381a6b8}}{{flag|additional-citations-needed}}. Spore print comparison (purplish-black for ''Psilocybe'' versus rusty-brown for ''Galerina'') and the presence of a bluing reaction are the most reliable field-level discriminators. Commercially obtained preparations claiming to contain psilocybin may be adulterated with synthetic substances — NBOMe-series compounds or other research chemicals have been detected in pressed tablets or powders sold as psilocybin. Ehrlich [[glossary:reagent-kit|reagent testing]] (DMAB) produces a purple/violet reaction indicating [[substance_class:chemical/indole]] presence but does not distinguish psilocybin from all synthetic indole imposters; definitive identification requires GC-MS or LC-MS/MS{{cite|doi=10.1016/bs.acc.2016.07.004|anchor=4203f3ef}}{{flag|additional-citations-needed}}. Cultivated mushrooms are susceptible to mold contamination (''Trichoderma'' spp., cobweb mold), implying potential mycotoxin exposure, though specific mycotoxin data in ''P. cubensis'' culture contamination are not available in the published literature. No ISO/IEC-accredited lab testing programs or Certificate of Analysis requirements currently apply to psilocybin mushroom products in any jurisdiction with regulated access. ===Psychological risks=== The most common adverse psychological event is the '''acute anxiety reaction''' — an overwhelming experience characterized by intense [[effect:anxiety]], fear, [[effect:paranoia]], panic, and dysphoric [[effect:confusion]]{{cite|doi=10.1177/0269881108093587|anchor=097ca69c}}. This risk is dose-dependent and context-dependent, mitigated by appropriate set, setting, and interpersonal support{{cite|doi=10.3389/fphar.2018.00897|anchor=5525bf9c}}. In the Carhart-Harris et al. (2016) open-label TRD study, transient anxiety was reported by all 12 participants during drug onset, with transient confusion or thought disorder in 9 of 12, and mild nausea in 4 of 12{{cite|doi=10.1016/s2215-0366(16)30065-7|anchor=da6b2d77}}. '''Persisting psychosis''' is rare but documented, particularly in individuals with personal or family history of psychotic disorders. This constitutes the principal screening [[glossary:contraindication]] in all clinical research protocols{{cite|doi=10.1177/0269881108093587|anchor=205fecb1}}{{flag|additional-citations-needed}}. '''Hallucinogen persisting perception disorder (HPPD)''' is characterized by persistent visual [[glossary:disturbance|disturbances]] — geometric [[glossary:hallucination|hallucinations]], halos, trails, [[effect:visual-haze-noise]] — persisting after [[substance_class:psychoactive/hallucinogen]] use ceases. Psilocybin and [[substance:lsd]] are the most commonly reported precipitants{{cite|doi=10.1037/pha0000597|anchor=c406caf3}}. HPPD has been documented in adolescents{{cite|doi=10.64719/pb.4525|anchor=e72c8c0d}} and adults, though precise prevalence estimates remain unavailable. ===Tolerance & dependence=== Psilocybin produces '''rapid tachyphylaxis''' via 5-HT₂A downregulation. Administration on consecutive days produces substantially diminished effects; clinical protocols space sessions by 1–4 weeks. Cross-tolerance with LSD and other [[glossary:serotonergic-psychedelics]] ([[substance:mescaline]], [[substance:dmt]]) is established{{cite|doi=10.1177/0269881108093587|anchor=c378e756}}{{flag|additional-citations-needed}}. Psilocybin produces '''no physical dependence''' and '''no clinically recognized withdrawal syndrome'''{{cite|doi=10.1177/0269881108093587|anchor=d2df9c10}}{{cite|doi=10.1016/j.neuropharm.2017.12.040|anchor=a4665098}}. The DSM-5 does not include a hallucinogen [[glossary:withdrawal]]. A systematic review of psilocybin for substance use disorders found no addiction signals{{cite|doi=10.1016/j.neubiorev.2025.106163|anchor=fbea5f7f}}. ===Drug Interactions=== '''MAOI + psilocybin mushrooms:''' Hypertensive urgency and emergency have been documented in [[glossary:case-report|case reports]]{{cite|doi=10.1007/s40263-025-01256-7|anchor=0acf1054}}. The mechanism involves dual MAO-A [[glossary:inhibition]]: exogenous MAOIs combined with endogenous β-carboline [[substance_class:pharmacological/monoamine-oxidase-inhibitor|monoamine oxidase inhibitors]] in the mushroom matrix{{cite|doi=10.1002/chem.201904363|anchor=0d180146}} severely impair [[glossary:serotonin]] [[glossary:metabolism]], potentiating both serotonergic and sympathomimetic effects. This combination should be avoided. '''SSRIs:''' Long-term SSRI use is associated with blunted subjective [[substance_class:psychoactive/psychedelic]] effects, likely via 5-HT₂A receptor downregulation. A post-hoc analysis of 233 treatment-resistant depression patients found that [[substance_class:psychoactive/antidepressant]] discontinuation prior to psilocybin treatment did not significantly affect clinical outcomes{{cite|doi=10.1016/j.jpsychires.2024.10.009|anchor=203f0468}}{{flag|additional-citations-needed}}. No [[glossary:serotonin-syndrome]] cases from SSRI + psilocybin specifically have been documented in the peer-reviewed literature. '''Lithium:''' The [[substance:lithium]] + psilocybin combination is flagged as potentially hazardous in published safety guidelines, with proposed mechanisms including serotonergic amplification and lithium's pro-convulsant effects at elevated levels{{cite|doi=10.1177/0269881108093587|anchor=246b1d25}}{{flag|additional-citations-needed}}. {{flag|safety-citation-needed}} Peer-reviewed case reports specifically documenting lithium-psilocybin [[glossary:seizure|seizures]] were not retrieved in this research session. '''Cannabis:''' Additive effects on anxiety and paranoia have been reported; no specific pharmacokinetic interaction is documented. Co-administration may intensify [[index:effects|subjective effects]]. '''CYP2D6 inhibitors:''' Drugs inhibiting [[glossary:cyp2d6]] (fluoxetine, paroxetine, bupropion, quinidine) may prolong psilocin exposure by impairing its primary [[glossary:metabolic-pathway]]{{cite|doi=10.3390/pharmaceutics17040411|anchor=0db7e615}}{{flag|additional-citations-needed}}. Direct clinical studies of this interaction for psilocybin are lacking. ===Contraindications=== '''Absolute contraindications:''' * '''Personal or family history of psychotic disorders''' (schizophrenia, schizoaffective disorder, bipolar I with psychotic features): psilocybin may precipitate or exacerbate [[glossary:psychosis]]. This is the primary exclusion criterion in all clinical research protocols{{cite|doi=10.1177/0269881108093587|anchor=18fe5b0e}}. * '''Concurrent MAOI use:''' risk of hypertensive emergency{{cite|doi=10.1007/s40263-025-01256-7|anchor=c73283d6}}. '''Relative contraindications:''' * '''Active suicidal ideation:''' exclusion criterion in clinical trials. [[effect:suicidal-ideation]] was reported across all dose groups (including 1 mg control) in a TRD population, consistent with the underlying condition rather than a drug-specific effect{{cite|doi=10.1056/nejmoa2206443|anchor=af55dd1c}}. * '''Cardiovascular disease:''' transient sympathomimetic effects ([[glossary:hypertension|elevated blood pressure]], heart rate); insufficient safety data in patients with established cardiovascular disease{{cite|doi=10.1007/s43440-023-00539-4|anchor=d0b006a4}}. * '''Concurrent lithium therapy:''' potential seizure risk{{cite|doi=10.1177/0269881108093587|anchor=f1a04792}}. {{flag|safety-citation-needed}} * '''Hepatic impairment:''' CYP2D6/[[glossary:cyp3a4]] metabolism; impaired hepatic function could prolong psilocin exposure. No published data exist in hepatically impaired patients. * '''Pregnancy:''' No published human safety or teratogenicity data exist. {{flag|safety-citation-needed}} * '''Adolescent and pediatric populations:''' No clinical trials have been conducted in minors; a case report of HPPD in a 16-year-old documents [[glossary:vulnerability]] in this population{{cite|doi=10.64719/pb.4525|anchor=24243d4c}}.

===International framework=== Psilocybin and [[substance:psilocin]] are listed as [[glossary:schedule-i]] substances under the 1971 United Nations [[glossary:convention-on-psychotropic-substances]]. Signatory states are obligated to prohibit them except for medical and scientific research. Psilocybin-containing mushrooms themselves were not explicitly listed in the Convention text — in part due to pressure from the Mexican government at the time of negotiation — creating jurisdictional ambiguity that several countries have recognized or exploited{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=db586834}}. ===Jurisdiction-specific status===

Jurisdiction	Classification	Key provisions
United States (federal)	Schedule I (Controlled Substances Act, 1970)	Psilocybin and psilocin Schedule I; mushrooms containing them treated as Schedule I material. DEA forwarded a rescheduling petition (Schedule I to II) in August 2025; outcome pending{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=de7313b2}}.
Oregon (US)	Regulated therapeutic access (Measure 109, 2020)	Licensed, supervised psilocybin services. First service centers opened 2023. Psilocybin remains illegal for unregulated personal use.
Colorado (US)	Decriminalized + regulated healing centers (Proposition 122, 2022)	Personal use, possession, cultivation, and gifting decriminalized for adults 21+. Regulated healing centers under development. Denver separately decriminalized psilocybin mushrooms in 2019.
Other US cities	Local decriminalization	Oakland CA, Santa Cruz CA, Ann Arbor MI, Seattle WA, Detroit MI, Northampton MA, and others have passed deprioritization or decriminalization measures.
Canada	Schedule III (Controlled Drugs and Substances Act)	Health Canada has authorized psilocybin access for palliative care and therapist training via Section 56 exemptions and the Special Access Program (2020–2022).{{flag|citation-needed}}
United Kingdom	Class A (Misuse of Drugs Act, 1971)	Most severe penalty classification. Research exemptions require Home Office license{{cite|name=psilocybin-legal-status|type=book|author=Multiple legal and regulatory sources|year=2025|title=Psilocybin legal status|anchor=c3b5a1cd}}.
Netherlands	Mushrooms banned (2008); truffles legal	Psilocybin mushrooms prohibited since 2008. Psilocybin-containing sclerotia (magic truffles) of ''P. tampanensis'', ''P. mexicana'', and related species remain legal and sold in licensed smart shops.{{flag|citation-needed}}
Germany	Controlled (Betäubungsmittelgesetz, BtMG)	Schedule I analogue. Expanded access for TRD patients has been authorized through compassionate-use pathways at select institutions.{{flag|citation-needed}}
Australia	Schedule 8 — Controlled Medicine (effective 1 July 2023)	Rescheduled from Schedule 9 (Prohibited) for treatment-resistant depression only. Must be prescribed by a specialist psychiatrist with TGA Authorised Prescriber approval; administered in a controlled medical environment with psychotherapy{{cite|name=tga-rescheduling-2023|type=book|author=Therapeutic Goods Administration|year=2023|title=Change of classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists|anchor=eecdeeb6}}.
Jamaica	Not scheduled	Psilocybin mushrooms are not prohibited under Jamaican drug law. Psilocybin retreat centers operate legally.
Brazil	Not explicitly scheduled	Psilocybin is not listed as a controlled substance; legal ambiguity exists in practice. A Phase 1 clinical trial using whole ''P. cubensis'' mushrooms is recruiting (NCT06898606).

===Treaty considerations=== The distinction between scheduled compounds (psilocybin, psilocin) and [[glossary:unscheduled]] biological material (mushrooms, truffles) under the 1971 UN Convention creates the legal space exploited by jurisdictions such as the Netherlands (truffles) and Jamaica (whole mushrooms). National implementations vary in whether they extend compound scheduling to the biological source organism or restrict [[glossary:prohibition]] to the isolated substances.